SUBSTRATE INSOLUBILITY DICTATES HSP104-DEPENDENTENDOPLASMIC RETICULUM ASSOCIATED DEGRADATION by Preston, George
SUBSTRATE INSOLUBILITY DICTATES 
HSP104-DEPENDENTENDOPLASMIC 
RETICULUM ASSOCIATED DEGRADATION 
by 
George Michael Preston 
BA in Biology, St. Mary’s College of Maryland, 2009 
Submitted to the Graduate Faculty of 
the School of Medicine in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy 
University of Pittsburgh 
ii 
UNIVERSITY OF PITTSBURGH 
SCHOOL OF MEDICINE 
This dissertation was presented 
by 
George Michael Preston 
It was defended on 
April 13, 2017 
and approved by 
Dr. Patrick Thibodeau, Assistant Professor, Department of Microbiology and Molecular 
Genetics 
Dr. Arohan Subramanya, Assistant Professor, Department of Cell Biology and Molecular 
Physiology 
Dr. Yong Wan, Professor, Department of Cell Biology and Molecular Physiology 
Dr. Andrew VanDemark, Associate Professor, Department of Biological Sciences 
 Dissertation Advisor: Dr. Jeffrey L. Brodsky, Professor, Department of Biological Sciences 
 iii 
Copyright © by George Michael Preston 
2017 
iv 
Misfolded proteins that reside in the Endoplasmic Reticulum (ER) are degraded through a quality 
control process known as ER-associated degradation (ERAD).  ERAD substrates are targeted to 
the 26S proteasome, but when proteasome function is compromised disease-associated ERAD 
substrates can aggregate in the cytoplasm.  Under normal conditions, how are these misfolded 
substrates identified by ERAD factors?  To address this question, a novel ERAD substrate, Q394X, 
was utilized.  Q394X contains two transmembrane domains fused to a truncated, C-terminal 
Nucleotide Binding Domain (NBD) from the well-characterized ERAD substrate, Ste6p*.   By 
exposing ER-enriched microsomes containing Q394X to the non-ionic detergent, dodecyl 
maltoside (DDM), Q394X was shown to be partially extracted from membranes and is less soluble 
than the wild type version of Q394X (Chimera A).  However, Q394X solubility was restored after 
addition of 6M urea to similar levels as Chimera A.  Interestingly, systematically truncating the 
NBD at sites both N-terminal and C-terminal to the truncation site in Q394X had varying effects 
on protein solubility and stability.   Two of the truncation mutants were as soluble as Chimera A, 
while the others exhibited the decreased solubility that was evident for Q394X.  By performing 
degradation assays, it was demonstrated that protein solubility and stability are positively 
correlated.    
To define how cells process the less soluble substrate, Q394X, I next investigated which 
chaperones might mediate its degradation.  I found that Q394X was stabilized in yeast when genes 
encoding members of the protein disaggregation machinery, including the AAA+ ATPase, Heat 
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Shock Protein of 104 kDa (Hsp104), were deleted.  Under these conditions of Q394X stabilization 
in the absence of Hsp104, I determined that Q394X aggregates in the ER membrane.  Furthermore, 
Hsp104 was shown to localize to punctae under these conditions, but formation of these punctae 
requires Q394X expression.  This aggregation of Q394X leads to a decrease in Q394X 
retrotranslocation by Cdc48.   These data provide evidence that Hsp104 acts to disaggregate 
Q394X in the ER membrane, which is required for efficient Q394X retrotranslocation and 
degradation. 
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1.0  INTRODUCTION 
In order to survive, cells must be capable of dealing with a variety of stresses, including 
temperature, oxidative stress, and mutations in their DNA.  These stresses often lead to problems 
in protein folding, which is linked to multiple human diseases.  In order to properly abrogate these 
stresses, cells possess a series of mechanisms, called quality control pathways.  These quality 
control pathways help rid the cell of problematic proteins.  One important quality control pathway 
is the endoplasmic reticulum associated degradation (ERAD) pathway (1).  
While ERAD consists of multiple steps ultimately leading to a protein’s degradation, one 
of the most important steps is the ubiquitination of misfolded proteins on the cytosolic face of the 
ER membrane.  This act of attaching ubiquitin to a protein targets it for degradation by the 26S 
proteasome.  In this introduction, I will discuss the foundation of what is known about the role of 
the ubiquitin-proteasome system (UPS) in ERAD.  I will address how proteins fold, and in the 
event that they misfold, how ERAD destroys them.  I will review the initial findings that have 
proven to be crucial for our current understanding of ERAD and how cells destroy misfolded 
proteins.  Finally, I will present what is currently known about the important factors of the UPS 
that play a role in ERAD, along with some of the alternative mechanisms that can be utilized to 
achieve protein degradation. 
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1.1 THE UBIQUITINATION PATHWAY 
The ubiquitination of a misfolded protein can represent a rate-limiting step during ERAD. But, 
before the substrate can be ubiquitinated, cells utilize an E1 ubiquitin-activating enzyme that 
hydrolyzes ATP to create a thiol-ester bond with the C-terminal carboxylate in ubiquitin (Figure 
1) (2-4). After activation, an E2 ubiquitin-conjugating enzyme is utilized to transfer ubiquitin to a 
substrate that may be bound to an E3-ubiquitin ligase. In other cases, the substrate may be linked 
to the E3 by a molecular chaperone (see below). Currently, only 1 E1 ubiquitin-activating enzyme 
and 11 E2 ubiquitin-conjugating enzymes have been identified in yeast, whereas there are 2 E1 
ubiquitin-activating enzymes and 35 E2 ubiquitin-conjugating enzymes that have been identified 
in humans (5, 6). In contrast, there are roughly 80 and 600 putative E3s in yeast and humans (7).  
Among these many ligases, three classes of E3s function in ERAD: (1) RING domain, (2) 
HECT domain, and (3) U-box domain E3s. RING domain and U-box domain E3s facilitate the 
transfer of ubiquitin from the E2 ubiquitin-conjugating enzyme to the substrate, whereas HECT 
domain E3s are directly ubiquitinated before the ubiquitin is transferred (8-12). Once the substrate 
becomes mono-ubiquitinated, an ubiquitin chain can be synthesized and elongated. The most 
prominent Lys in ubiquitin that is elongated in this manner and used to target substrates for 
degradation is Lys-48 (4, 13-15). However, substrate ubiquitination via Lys-11-derived isopeptide 
linkages are also recognized by the proteasome (16). A more recently discovered class of 
components of the ubiquitination machinery are the ubiquitin chain elongation factors, called E4s 
(17). As the name implies, the activity of the E4 elongates the polyubiquitin chain in order to more 
effectively recruit factors that facilitate substrate degradation and expedite proteasomal 
degradation (18-20). After an ERAD substrate has been adequately ubiquitinated (Figures 2 and 
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3), the p97/Cdc48 complex is recruited to the substrate by its cofactors, Ufd1, Npl4, and in some 
cases Ubx2 (UBXD8 in mammalian cells) (21, 22). 
Interestingly, the viral protein, US11, which promotes the ERAD of specific substrates (see 
below), interacts with p97 in a ubiquitin-independent manner in mammalian cells (23). However, 
most p97/Cdc48 substrates are ubiquitinated. The recruitment of the p97/Cdc48 complex leads to 
substrate ‘retrotranslocation’ (or ‘dislocation’ for membrane proteins) from the ER and into the 
cytosol, where it is bound and shuttled to the 26S proteasome by delivery factors, such as Rad23 
and Dsk2, in yeast (24). Interaction of Rad23 with the Cdc48–Ufd1–Npl4 complex is mediated by 
another Cdc48 cofactor, the E4 Ufd2 (20). Once Rad23 and Dsk2 bind the Cdc48 complex, they 
link the complex to the proteasome through a component that resides on the proteasome ‘cap’ (also  
known as the 19S particle or PA700), Rpn1 (25). In addition to binding by Rad23–Dsk2– Rpn1, 
another component of the 19S cap, called Rpn10, can bind ubiquitin in an Rad23-independent 
manner (26). After substrate binding to the 19S particle of the proteasome, the proteasome-
associated deubiquitinating enzymes (DUBs), Ubp6 and Rpn11, cleave the ubiquitin chain from 
the substrate, and the substrate is subsequently threaded into the 20S core particle and degraded 
(27-31). Entry into the 20S particle requires the activity of six AAA-ATPases that drive substrate 
entry into the core and facilitate the opening of an aperture that otherwise retains the 20S particle 
in a closed state (32, 33).   
 
 
 
 
 
 4 
Figure 1. The ubiquitination pathway 
The cytosolic E1 ubiquitin-activating enzyme hydrolyzes ATP to activate the ubiquitin molecule. 
ATP hydrolysis and the formation of a transient AMP-derivative lead to the formation of a 
thioester bond between the E1 and the C-terminus of ubiquitin. The E1 then transfers ubiquitin to 
one of the ∼11 yeast or the ∼35 mammalian E2 ubiquitin-conjugating enzymes. The covalently 
bound ubiquitin–E2 adduct then binds one of the ∼80 yeast or the ∼300 mammalian E3 ubiquitin 
ligases. The E3 enzymes may also be bound to the ERAD substrate and facilitate transfer of 
ubiquitin to the substrate, or a chaperone intermediate (not shown) may facilitate transfer. Some 
E3 ubiquitin ligases (e.g. HECT domain E3s) become covalently modified with ubiquitin during 
ERAD substrate modification, while other E3s (e.g. RING and U-box domain proteins) facilitate 
the transfer of ubiquitin from the E2 ubiquitin-conjugating enzyme to the substrate. Importantly, 
select E2 ubiquitin-conjugating enzymes and E3 ubiquitin ligases are cytoplasmic, while others 
reside at the ER membrane. Once a substrate is ubiquitinated by an E3 ubiquitin ligase, other 
enzymes, such as E4s, may further extend the ubiquitin chain on the ERAD substrate. 
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1.2 PROTEIN MISFOLDING AND ERAD 
In cells, proteins must adopt a specific fold that allows them to perform their required functions.  
Early in vitro studies investigating protein folding demonstrated that the information needed for 
proteins to fold is contained in the amino acid sequence (34).  However, it is not feasible for 
proteins to sample all potential partially folded conformations, as the time it would take to fold 
even small proteins would be well beyond the time-frame in which proteins are known to fold (35).  
Instead, it is believed that proteins adopt short-range interactions within their local environment, 
which helps to guide them to adopt their functional fold (36).  These intramolecular interactions 
lead to the orientation of hydrophobic regions towards the interior of the protein, formation of and 
interactions between secondary structures within the protein, and the alignment of regions for post-
translational modifications (37).   Partial folding through intramolecular interactions leads to the 
adoption of more ordered structures, which then leads to the peptide residing in lower free energy 
states.  By having large differences in free energy between intermediate folded forms and the native 
conformation, proteins are more likely to reside in their properly folded state (38).   Using free 
energy differences to drive proper folding is important, because the lower free energy states have 
fewer potential alternative states, which allows proteins to fold more quickly and/or efficiently 
(36).  However, it is still possible that native peptides sample these incompletely folded states, as 
some populations of protein folding intermediates have been observed in vitro (39).    It has been 
suggested that these folding intermediates may help the protein to adopt its properly folded state; 
alternatively, they could represent misfolded, trapped states of the protein (40).  Regardless, in 
vitro folding studies have been used to learn a lot about the dynamics of protein folding.  
While many of the principles of protein folding are likely the same in vivo as have been 
observed in vitro, proteins face a different problem in vivo.  In cells, proteins often fold co-
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translationally or after being inserted into a specific organelle, such as the endoplasmic reticulum 
(ER) (41, 42).  In these cellular environments, newly synthesized peptides are exposed to a variety 
of factors that affect protein folding, including varying ion concentrations, oxidative states, etc… 
(43, 44).  However, one aspect of the cellular folding environment that is particularly problematic 
for protein folding is the level of protein crowding that exists inside the cell (45).  Protein crowding 
increases the risk of newly synthesized peptides adopting improper conformations or increases the 
potential for improper protein-protein interactions (46).  In order to combat these improper protein-
protein interactions and to assist with the proper folding of newly synthesized peptides, the cell 
utilizes a class of proteins called molecular chaperones.   
Molecular chaperones perform a variety of functions in the cell, including assisting in the 
folding of newly synthesized proteins, assisting with refolding of denatured/aggregated proteins, 
facilitating protein trafficking, and degrading terminally misfolded proteins (47).  The basic 
mechanism of molecular chaperone recognition and binding to proteins is through the exposure of 
hydrophobic amino acid side chains in the peptide (47).  While different molecular chaperone 
classes may perform varying functions in the cell, molecular chaperones can be split into two 
general groups: 1) The ATP-dependent chaperones and 2) the ATP-independent chaperones.  ATP-
dependent molecular chaperones, such as the Hsp70s and chaperonins, initially assist in protein 
folding by binding exposed hydrophobic stretches and preventing improper protein-protein 
interactions (47).  Upon ATP hydrolysis, these molecular chaperones release the substrates, 
thereby allowing them to fold.  The ATP-independent chaperones, such as the small heat shock 
proteins (sHSPs), are believed to bind hydrophobic stretches and maintain substrate solubility until 
the protein can be processed further by other chaperones (48).  As mentioned above, some 
chaperones are also known to play important roles in protein degradation.  This is especially true 
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in the ER where molecular chaperones, such as the ER-luminal Hsp70, Kar2, and the ER lectin, 
Yos9, bind to misfolded proteins and serve an important role in the selection of proteins to be 
degraded (49, 50).                  
Misfolded, aggregation-prone proteins present a distinct challenge to cells.  Specifically, 
they must be destroyed prior to aggregation, as protein aggregation can be toxic to cells (51).  In 
the ER, the mechanism of ERAD is crucial for the clearance of misfolded proteins and to prevent 
aggregation in the ER (Figures 2 and 3, (1)).  Initially, ERAD substrates are recognized as 
terminally misfolded by a series of factors, including molecular chaperones and components of the 
UPS (49, 50, 52-56).  Once a protein has been selected for ERAD, the components of the UPS 
append a poly-ubiquitin chain to the terminally misfolded protein (For more, see section 1.1 and 
1.3).  This ubiquitin chain serves as a recruiting signal for the AAA+ ATPase, Cdc48/p97, at the 
ER membrane, which is mediated specifically by the Cdc48/p97 cofactors, Ufd1 and Npl4 (20, 
23).  Once Cdc48/p97 binds to the ERAD substrate, it is removed from the ER and into the cytosol, 
where it is further processed and degraded by the 26S proteasome (57).        
1.3 THE FIRST LINK BETWEEN THE UBIQUITIN PATHWAY AND ERAD 
Ubiquitination was first identified as an ATP-dependent process important for protein degradation 
in the late 1970s/early 1980s (58, 59). However, it was not until the 1990s that a component of the 
ubiquitination machinery was discovered at the ER (60). This factor is an ER membrane-resident 
E2 ubiquitin-conjugating enzyme, Ubc6. It was shown that deleting UBC6 leads to the rescue of a 
sec61 mutant allele that is defective for protein translocation, or entry into the ER. In the absence 
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of Ubc6, the mutant Sec61 channel has a longer half-life, which allows for partial rescue of protein 
translocation.   
Other early discoveries led to the identification of proteins in the ER that were ubiquitinated. At 
least initially these were substrates that trafficked through the secretory pathway, but were retained 
in this compartment due to errors in folding or maturation. One of the most notable substrates 
identified was the cystic fibrosis transmembrane conductance regulator (CFTR), whose failure to 
properly fold and mature due to rapid degradation is the cause of cystic fibrosis (CF) (61, 62). 
Degradation of both immature forms of the wild-type and the ΔF508 mutant form of CFTR, which 
accounts for the majority of CF cases, was shown to be dependent on both the E1 ubiquitin-
activating enzyme and the 26S proteasome for degradation. CFTR and ΔF508 were also directly 
shown to be ubiquitinated.    
Substrates used to identify additional components of the ubiquitination machinery in the yeast ER 
included a mutated form of a vacuole-targeted protein, carboxypeptidase yscY, which was 
subsequently termed CPY* (63). Analyses of CPY* degradation uncovered the importance of an 
E2 ubiquitin-conjugating enzyme, Ubc7, as well as the proteasome in removing this trapped 
protein from the ER (63-65). In parallel, an enzyme that catalyzes the rate-limiting step in 
cholesterol synthesis, known as hydroxymethylglutaryl coenzyme A reductase, was known to be 
metabolically regulated and degraded in the ER (66, 67). By examining the genetic requirements 
for the degradation of the yeast homolog, Hmg2, three HRD genes that are important for the 
degradation of Hmg2 at the ER were identified (68). Two of these HRD genes, HRD1 and HRD3, 
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Figure 2. Function of the Hrd1 complex during ERAD in yeast 
In the first step during ERAD (‘Recognition’), a misfolded substrate is recognized by a subset of 
factors, namely Kar2 (ER luminal Hsp70 chaperone), Yos9 (ER luminal lectin), Der1 
(transmembrane core Hrd1 complex member), or directly by the E3, Hrd1. Once the substrate 
has been recognized, the substrate is transferred to the Hrd1 complex for polyubiquitination. 
Kar2 and Yos9 bind to the Hrd1 core complex member, Hrd3, and the substrate is transferred to 
Hrd1 (‘Ubiquitination’). Der1 is bound by Usa1, which helps link Der1 to Hrd1. Cue1 is an ER 
membrane protein that recruits the E2 ubiquitin-conjugating enzyme, Ubc7, to the Hrd1 
complex. After the substrate is polyubiquitinated, the dislocation machinery is linked to the 
complex. This dislocation complex consists of the membrane protein, Ubx2, which helps recruit 
the AAA+ ATPase, Cdc48. Cdc48 is stabilized at the Hrd1 complex through an interaction with 
Hrd1 and through an interaction with the Cdc48 cofactors, Ufd1 and Npl4, with the polyubiquitin 
chain. Assembly is believed to be due to Ufd1 binding to the polyubiquitin chain, as yeast Npl4 
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lacks a zinc finger domain. Another class of cofactors that bind Cdc48 and affect 
retrotranslocation includes DUBS, such as Otu1 (not shown here). Once bound to the substrate, 
Cdc48 hydrolyzes ATP and liberates the substrate from the ER (‘Retrotranslocation’). The 
Cdc48 cofactor, Ufd2, then extends the polyubiquitin chain and interacts with the ubiquitinated 
protein shuttles, Rad23 and Dsk2 (‘Degradation’). Although not shown in this figure, ubiquitin 
chains may be trimmed by DUBS prior to substrate passage through Cdc48 and then extended 
again by Ufd2. Rad23 and Dsk2 can also interact with the 19S cap of the cytosolic 26S 
proteasome, which leads to substrate degradation. Another DUB associated with the 19S cap of 
the proteasome, called Rpn11 (not shown), removes the polyubiquitin chain attached to the 
ERAD substrate, so it efficiently threads into the core of the 26S proteasome for degradation. 
 
 
are vital for the ubiquitination and degradation of many other ERAD substrates (Table 1) (69-71). 
Hrd1 is one of the major ER membrane-resident E3s involved in ERAD in yeast and is the central 
component of the Hrd1 complex, which is conserved between yeast and mammals (see below). 
Hrd3 is an ER membrane-resident protein that interacts with Hrd1. When HRD3 is deleted, Hrd1 
degradation increases, leading to a loss of function of the Hrd1 complex (70, 72, 73). Finally, the 
major histocompatability complex class I (MHCI) protein was utilized to identify a novel 
mechanism of immune evasion by human cytomegalovirus (HCMV). A virally encoded, ER-
localized protein, US11, triggered nascent MHCI heavy chain transport from the ER into the 
cytosol, where it is acted upon by a cytosolic N-glycanase, ubiquitinated, and subsequently, 
degraded by the 26S proteasome (74, 75). Together, these substrates have proved essential for 
continued analysis of the factors important for ubiquitination and degradation during ERAD. 
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1.4 EXPANDING THE LINKS BETWEEN UBIQUITINATION AND ERAD 
1.4.1 Identification of contributing E3s and their associated complexes 
While these initial breakthroughs were crucial to better understand the importance of protein 
ubiquitination in ERAD, the years that followed led to the identification of additional factors, 
complexes, and substrates associated with this process (Table 1). In yeast, there are two primary 
E3s, Hrd1 and Doa10, that are required for ubiquitination and degradation; however, there are 
currently eight E3s that play some role during the ubiquitination of ERAD substrates in yeast. In 
mammals, there are four E3s, Hrd1, TEB4, gp78, and CHIP, which are associated with the 
degradation of several notable ERAD substrates, but ∼19 E3s have been linked more generally to 
ERAD (Table 1). The expanded number of E3s involved in ERAD in mammals when compared 
with yeast is most probably due to the greater number of potential substrates (e.g. transmembrane 
proteins) in mammalian cells. 
While Hrd1 was the first E3 linked to the ERAD pathway, it was appreciated later that the Hrd1 
complex (Figure 2) ubiquitinates substrates that possess misfolded regions in their ER luminal 
(ERAD-L) or membrane spanning domains (ERAD-M) (68, 69, 71, 76, 77). In yeast, the Hrd1 
complex consists of Hrd3, Usa1, Der1, Dfm1, Yos9, Kar2, Ubc7, and Cue1 (73, 78). While these 
factors are all known to be a part of the Hrd1 complex, not all of them are considered 
components of the core Hrd1 complex. When the complex was purified, Hrd3, Usa1, Der1, and 
Yos9 co-purified, thus defining components of the core complex (78). As noted previously, Hrd3 
stabilizes the Hrd1 oligomer, but also binds glycosylated misfolded luminal substrates by 
interacting with a luminal lectin, Yos9, as well as nonglycosylated misfolded substrates via an 
Hsp70 molecular chaperone, Kar2 (49, 50, 52, 70). Until recently, it was difficult to study the 
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role of Hrd3 in ERAD due to the increased turnover of Hrd1 when HRD3 is deleted. However, 
when the ubiquitin-like domain of Usa1 is removed, Hrd1 remains stable and a direct role for 
Hrd3 in ERAD was established (79). Der1 also binds soluble luminal substrates and interacts 
with Hrd1 through Usa1 (80, 81). In addition, a Der1 homolog, Dfm1, interacts with Hrd1 and 
the E3 ligase, Doa10, and helps degrade a Doa10 substrate, Ste6* (21, 82). In a mechanism 
believed to be independent of ERAD, Dfm1 also interacts with Cdc48 in the absence of Ubx2 
(82, 83). As the Hrd1 complex engages substrates, Ubc7 is recruited to the ER membrane by a 
transmembrane protein, Cue1 (84, 85). In addition to Ubc7, another E2, Ubc1, ubiquitinates 
select ERAD substrates (69, 86). Hrd1 also recruits the ER membrane protein, Ubx2, to the 
complex, which anchors Cdc48 to the membrane (21, 22). Ubx2 anchoring facilitates efficient 
substrate retrotranslocation. Some evidence suggests that Der1 and the mammalian homolog 
(also see below) may act as the retrotranslocation channel for substrates, or at least are intimately 
associated with the retrotranslocation process (87-91), while other evidence suggests that Hrd1 
could serve as the channel (92, 93). In either case, this would position the ubiquitination 
machinery near the site of retrotranslocation.   
Mammalian homologs for many of the components discussed above were subsequently 
identified (Figure 3).  The mammalian homolog of Hrd1, also called HRD1 or synoviolin (94, 95), 
is important to ubiquitinate several ERAD substrates (Table 1). Other mammalian homologs of 
yeast Hrd1 complex members have been identified as well: SEL1L (Hrd3), HERP (Usa1), 
DERLIN-1, DERLIN-2, DERLIN-3 (Der1), OS-9 and XTP3-B (Yos9), BiP (Kar2), UBE2G2 
(Ubc7), and Aup1 (Cue1) (78, 89, 96-102). 
 
 
 13 
  
Figure 3. Function of the Hrd1 complex during ERAD in mammalian cells 
In the first step during ERAD (‘Recognition’), a substrate is recognized by a group of luminal and 
membrane-associated factors, namely BiP (Hsp70 chaperone), OS9 and XTP-3 (lectins), Derlin1 
(transmembrane core Hrd1 complex member), and/or HRD1. While OS9 and XTP-3 recognize 
misfolded ER luminal glycosylated substrates, they may also recognize nonglycosylated 
substrates. The substrate is then transferred to the HRD1 complex and polyubiquitinated. BiP, 
OS9, and XTP-3 bind the HRD1 core complex member, SEL1L, and the substrate is next 
transferred to HRD1 (‘Ubiquitination’). DERLIN1 is bound by HERP1, which helps link Derlin1 
to HRD1. The mammalian HRD1 complex can utilize DERLIN2 and DERLIN3 as well. AUP1 is 
a Cue domain-containing ER membrane protein that recruits the E2 ubiquitin-conjugating enzyme, 
UBE2G2, to the HRD1 complex. Once polyubiquitinated, the dislocation machinery is recruited 
to the HRD1 complex. This complex includes the membrane protein, UBXD8, which augments 
p97 recruitment to the HRD1 complex. Along with UBXD8, the HRD1 complex can utilize 
another protein, called UBXD2, to recruit p97. p97 is further stabilized at the HRD1 complex 
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through interaction with HRD1 along with the p97 cofactors, UFD1 and NPL4, via the 
polyubiquitin chain. In an alternative mechanism of p97 recruitment, the cytoplasmic protein, 
VIMP, binds p97 (not shown) at the HRD1 complex through a VIMP interaction domain in 
DERLIN1. Another class of cofactors that bind p97 and act during ERAD include DUBS, such as 
YOD1 (not shown). Once bound to the substrate, p97 hydrolyzes ATP and removes the substrate 
from the ER (‘Retrotranslocation’). After retrotranslocation, the p97 cofactor and a mammalian 
homolog of Ufd2, UBE4A/B, may extend the polyubiquitin chain and associate with the protein 
shuttles, RAD23A, and a specific UBIQUILIN, UBQLN2 (‘Degradation’). Ubiquitin chains may 
be trimmed by DUBS prior to substrate transit through p97 and could then be extended again by 
UBE4A/B. RAD23A and UBIQUILIN also interact with the 19S cap of the cytosolic 26S 
proteasome, which facilitates substrate degradation. In addition, there is a DUB associated with 
the 19S cap of the proteasome, RPN11, which removes the polyubiquitin chain attached to the 
ERAD substrate, which aids efficient entry of the substrate into the 26S proteasome core. 
Perhaps not surprisingly, mammalian HRD1 complex members have also been 
implicated in the ubiquitination of ERAD substrates (Table 1). As in yeast, HRD1 functions in 
the degradation of both glycosylated (utilizing EDEM1, DERLIN-2, DERLIN-3, OS-9, XTP3-B, 
and SEL1L) and nonglycosylated substrates (utilizing BiP, HERP, and DERLIN-1) (1, 53-56). 
While HRD1 activity for glycosylated substrates is generally thought to function in a SEL1L-
dependent manner (96, 100), another HRD1 regulator, the ER membrane-resident protein 
FAM8A1, binds and regulates HRD1 function in an SEL1L-independent manner (103). After 
substrate association with the HRD1 complex, AUP1, which contains a Cue domain homologous 
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to that found in the yeast Cue1 protein, binds the complex and recruits UBE2G2 through its 
G2BR domain (100, 101, 103-106). For some substrates, HRD1 also utilizes the Ubc6 homolog, 
UBE2J1 (107). Which of these E2 ubiquitin conjugating enzymes is the predominant enzyme for 
HRD1 is an open question. Mammalian HRD1 also binds to other factors that play a role in 
ERAD. For example, Hrd1 associates with UBXD2 and UBXD8, which function similarly to 
yeast Ubx2 in anchoring p97 to the ER membrane. Furthermore, UBXD2 recruits the 
mammalian Dsk2 homolog, called UBIQUILIN (100, 108-111), to the Hrd1 complex, whereas 
UBXD8 recruits a cytosolic chaperone, BAG6 (112, 113). Recently, UBIQUILIN and BAG6 
were shown to function as chaperones as well, suggesting that they play an important role as 
holdases for dislocated proteins prior to degradation (112, 114). Yet, another factor that binds the 
HRD1 complex and recruits p97 is VIMP (VCP-interacting membrane protein) (115).  VIMP 
localizes to the HRD1 complex via association with DERLIN-1 and subsequently binds p97. 
HRD1 and DERLIN-1 are also capable of binding p97, suggesting that they contribute to the 
maintenance of p97 residence at the ER membrane (116, 117).  
Table 1. List of cellular factors shown to affect the ubiquitination of ERAD 
substrates 
Factors Select Substrates Notes References 
E1 Ubiquitin Activating Enzymes1 
Yeast 
Uba1 (118) 
Mammalian 
E1a, E1b Isoforms resulting 
from alternative 
splicing 
(119-121) 
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E2 Ubiquitin Conjugating Enzymes2 
Yeast 
Ubc1 CPY*, Hmg2 Cytosolic E2 that is 
recruited to the ER 
membrane by Hrd1 
(69, 86) 
Ubc6 Sss1, sec61, Deg1-Ura3, 
Pma1‐D378N, Ste6* 
Integral ER 
membrane E2 
(64, 122-125) 
Ubc7 Hmg2, CPY*, SSS1, sec61, 
Deg1-Ura3, Pma1‐D378N, 
Ste6* 
Cytosolic E2 that is 
recruited to ER 
membrane by Cue1 
(63-65, 69, 71, 122-
126) 
Ubc2 Ste6* Cytosolic E2 only 
shown to be 
important with Ubr1 
(127) 
 
Mammalian 
UBE2D1 CFTR, p53, APP Homolog of yeast 
Ubc4/5 
(121, 128, 129) 
UBE2J1 MHCI, CFTR, TCRα, OS-
9, EDEM, SEL1L 
Homolog of yeast 
Ubc6 
(104, 107, 130, 
131) 
UBE2K MHCI Homolog of yeast 
Ubc1, used by viral 
protein US11 
(132) 
UBE2G2 HERP, gp78, CD3-δ, 
TCRα, InsP3R 
Homolog of yeast 
Ubc7 
(106, 133-135) 
 
E3 Ubiquitin Ligases 
Yeast 
Hrd1 CPY*, sec61-2, Hmg2, 
pdr5-C1427Y, Huntingtin, 
unglycosylated PrP,  
Integral ER 
membrane E3 
(68, 69, 76, 136-
139) 
Doa10 Deg1-Ura3, Ubc6, Ste6*, 
Erg1, α, β, γ subunits of 
ENaC, Pca1, Zrt1, Sbh2 
Integral ER 
membrane E3 
(123, 125, 140-144) 
Rsp5 CPY* Cytosolic E3 required 
only when substrates 
are significantly 
overexpressed and 
cells are under 
oxidative stress 
(145, 146) 
Ubr1 Ste6*, CFTR Cytoplasmic E3 (127) 
Asi1/Asi1/Asi3 Erg11 Integral nuclear 
membrane-localized 
E3 complex 
(147, 148) 
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Mammalian 
HRD13 HMGR, TCR-α, CD3-δ, 
MHCI, NHK, APP, α1AT, 
gp78, NS1 LC, CD95/Fas, 
p53, CD147 
Homolog of yeast 
Hrd1 
(94, 96, 107, 121, 
129, 149-155) 
TEB4 Type 2 Iodothyronine 
Deiodinase (D2), squalene 
monooxygenase (SM), 
HMGR 
Homolog of yeast 
Doa10 
(142, 156-158) 
gp78 CD3-δ, apoB100, CFTR, 
HMGR, α1AT, Kai1, 
Cytochrome P450 3A 
Homolog of yeast 
Hrd1 
(106, 159-165) 
CHIP CFTR, NCC, Pael-R, 
Cytochrome P450 3A 
Cytoplasmic E3 (128, 165-169)  
RMA1/RNF5 CFTR Integral ER 
membrane resident 
E3 
(130, 161, 170) 
TRC8 MHCI, SREBP-1, SREBP-
2, Heme oxygenase-1, 
XBP1u, α1 integrin, α2 
integrin, α4 integrin, β1 
integrin, thrombomodulin, 
PTPRJ and IL12 receptor 
β1 
Integral ER 
membrane resident 
E3 
(171-175) 
SCFFbx2 Pre-integrin β1, TCR-α, 
CFTR 
Cytoplasmic/ ER 
membrane-associated 
E3 
(176, 177) 
SCFFbx6 TCR-α Cytoplasmic/ ER 
membrane-associated 
E3 
(178) 
SCFβ-TrCP CD4, Tetherin Cytoplasmic E3 
utilized by HIV 
protein, Vpu 
(179, 180) 
RNF4 CFTR Cytoplasmic/Nuclear 
E3 that recognizes 
poly-SUMOylated 
substrates 
(181) 
RNF103 Auto-ubiquitination Integral ER 
membrane resident 
E3 
(182) 
RNF170 Inositol 1,4,5-trisphosphate 
(IP3) 
Integral ER 
membrane resident 
E3 
(183) 
RNF185 CFTR Integral ER 
membrane resident 
(184) 
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E3 that is 
homologous to 
RMA1/RNF5 
PARKIN Pael-R, mutant 
glucocerebrosidase 
Cytoplasmic E3  (169, 185) 
TRIM13 CD3-δ, Cav1.2 Integral ER 
membrane resident 
E3 that also plays a 
role in autophagy 
(186, 187) 
SMURF1 WFS1 Cytoplasmic/Nuclear-
localized E3 
(188) 
TMEM129 MHCI Integral ER 
membrane resident 
E3 utilized by 
HCMV 
(189) 
NIXIN/ZNRF4 calnexin Integral ER 
membrane resident 
E3  
(190) 
NRDP1 ErbB3 Cytoplasmic E3 (191) 
SYVN1 CFTR ER/Cytoplasmic E3 (177) 
 
Ubiquitination Modifiers 
Yeast 
Cue1 CPY*, Hmg2, KWW Required for Ubc7 
activation and 
Integral ER 
membrane protein 
(77, 84, 85, 192) 
Hrd3 Hmg2, CPY*, sec61-2, 
Pdr5*, unglycosylated PrP 
Integral membrane 
component of Hrd1 
complex 
(52, 68, 70, 79, 
138) 
Ssa1 Ste6*, Pma1‐D378S, CFTR Cytosolic Hsp70 (19, 141, 193, 194) 
Ydj1 Ste6*, Pma1-D378S Cytosolic Hsp40 that 
can be farnesylated 
(19, 141, 193) 
Hlj1 Ste6*, CFTR Homologue of Ydj1 (19, 195) 
Otu14,5 CPY*, Spt23 Cytosolic 
deubiquitinating 
enzyme 
(92, 196, 197) 
Ufd34 Spt23 Cytosolic ubiquitin 
chain length regulator 
(197) 
Ufd24 Ole1, HMG2, DEG1Sec62 Cytosolic ubiquitin 
extension enzyme 
(E4) 
(17, 20) 
 
Mammalian 
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HDJ2 CFTR, Pael-R Homolog of yeast 
Ydj1 
(128, 169, 198) 
SEL1L NHK, TTRD18G, RI332, 
tyrosinase 
Homolog of yeast 
Hrd3 
(96, 103, 199) 
FAM8A1 NHK, TTRD18G Hrd1 binding partner 
believed to regulate 
Hrd1 function 
(103) 
HSC70 CFTR, Pael-R, ApoB100, 
ENaC, NCC     
Homolog of yeast 
Ssa1 
(128, 169, 200-203) 
DNAJB12 CFTR Integral ER 
membrane resident 
Hsp40 
(170, 204)  
USP134 Ubl4A Deubiquitinating 
enzyme 
(205, 206) 
USP19 CFTR, TCRα Integral ER 
membrane resident 
deubiquitinating 
enzyme 
(207) 
USP25 CD3-δ, APP, CFTR Integral ER 
membrane resident 
deubiquitinating 
enzyme 
(208) 
AUP1 MHCI, NHK, HMG CoA Integral ER- 
membrane cue 
domain containing 
protein that recruits 
Ube2g2 to ER 
membrane and lipid 
droplets 
(101, 209) 
YOD14,5,6 RI332, NHK, TCRα Homolog of yeast 
Otu1 
(210) 
ATAXIN-34 TCRα, CD3-δ, BACE457Δ Deubiquitinating 
enzyme 
(205, 211, 212) 
UBE4B4  Homolog of yeast 
Ufd2 
(17, 20) 
NEDD8 CFTR Cytoplasmic 
Ubiquitin-like protein 
(177) 
1 Substrates for the E1 are the E2s 
2 Some ERAD E3s facilitate the degradation of cytosolic proteins (213) 
3 Substrates for the E2s are the E3s 
4 These components can recognize and bind to the Cdc48/p97 complex in the cytosol 
5 May trim ubiquitin chains prior to entry into p97/Cdc48 
6 May also act on ERAD machinery (214) 
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The other ERAD-associated E3 complex in yeast centers around the nuclear membrane/ER 
membrane localized E3, Doa10 (140). While Hrd1 functions in collaboration with a variety of 
other proteins, Doa10 acts predominantly with three different components in a ubiquitination 
complex: Ubc6, Ubc7, and Cue1 (78, 123, 140). Recent data suggest that Ubc6 initially mono-
ubiquitinates the substrate, whereas Ubc7 creates the polyubiquitin chain by adding subsequent 
ubiquitin moieties (215). In contrast with Hrd1, which ubiquitinates substrates containing 
misfolded lesions in the ER lumen and ER membrane, Doa10 substrates contain a cytosolic lesion 
(ERAD-C) (77). As a result, cytosolic chaperones, such as an Hsp70, Ssa1, and the cytosolic 
Hsp40s, Ydj1 and Hlj1, are also important for the degradation of Doa10-dependent substrates (19, 
141, 193-195).  Like Hrd1, Doa10 recruits Ubx2 to the complex, allowing for increased efficiency 
of substrate retrotranslocation by Cdc48 (21, 22). In the mammalian system, TEB4/MARCH-VI 
(158, 216) is the Doa10 homolog (142, 156-158). TEB4/MARCH-VI acts in a complex with the 
E2 ubiquitin-conjugating enzyme, UBE2G1 (158). Similar to the situation observed in yeast, 
cytosolic chaperones, such as HSC70, DNAJB12, and HDJ2 (128, 170, 198, 201, 204), can help 
degrade some ERAD substrates and UBXD8 can aid in substrate retrotranslocation.   
The mammalian E3, gp78 (159), is another major E3 ligase for ERAD substrates in 
mammalian cells. gp78 is an ER membrane protein that is similar to HRD1 and utilizes UBE2G2. 
This interaction is through an embedded G2BR domain (106). While gp78 clearly functions as an 
E3 during ERAD, there is also evidence that it acts as an E4 in co-operation with other E3s (161). 
Additional evidence suggests that gp78 participates in substrate retrotranslocation downstream of 
HRD1 (217). The diversity in gp78 function may reflect substrate specificity and partner 
specificity, which represent an important area of future study. Regardless, similar to HRD1 and 
TEB4/MARCH-VI, gp78 also recruits UBXD2 or UBXD8 to help cement p97 at the ER 
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membrane.  Alternatively, gp78 can directly interact with p97 through its VIM (VCP-interacting 
motif) domain (116, 218).   
One of the earliest ERAD-requiring E3s identified in mammalian cells was the cytosolic 
HSC70-interacting protein, CHIP. While several ERAD substrates were identified that require 
CHIP activity, the best-studied substrate is CFTR (128). Interestingly, CHIP requires HSC70 as a 
cofactor for function, but CHIP can also act in collaboration with other E3s, such as PARKIN 
(128, 167, 169). This may reflect the ability of CHIP to act cooperatively, or it may reflect an E4-
type activity. For example, while RMA1 and CHIP both facilitate mutant CFTR degradation, the 
dependence on each E3 was linked to the subdomain in which the mutation resided (130). RMA1 
recognizes mutations early in the protein sequence and in the transmembrane domains of CFTR, 
whereas CHIP is believed to recognize cytoplasmic domains and the C-terminal second 
nucleotide-binding domain in CFTR.   
Several additional E3 ubiquitin ligases have been identified that act on ERAD substrates 
in both yeast and mammalian cells (Table 1).  Many of these enzymes are required for the 
degradation of only a few substrates, yet this might again reflect the fact that the universe of 
identified and characterized ERAD substrates is relatively small.  In yeast, the cytosolic E3, Ubr1, 
is required along with Hrd1 and Doa10 during the degradation of Ste6* and CFTR, and employs 
the cytosolic E2, Ubc2 (127). However, Ubr1 is better known for its role in degrading unstable N-
end rule substrates (219). In addition, Rsp5, a cytosolic/Golgi-resident E3, ubiquitinates 
overexpressed CPY* and other select substrates when cells are exposed to oxidative stress (145, 
146).  Finally, in yeast, the nuclear membrane E3 complex, consisting of Asi1, Asi2, and Asi3, 
plays a role in the destruction of Erg11, a sterol synthesis component that resides in the ER (147, 
148).  
Roles for specialized E3s in ERAD have also been studied in mammalian cells. Some of 
these enzymes are important only under select conditions. For instance, SCFβ-TrCP and TMEM129 
are utilized by viruses to ubiquitinate ER-localized factors associated with the immune system 
(179, 180, 189). Other ligases recognize specific protein classes: the cytosolic E3s SCFFbx2 and 
SCFFbx6 target glycosylated ERAD substrates in the cytosol and modify them prior to 
proteasomal degradation (176, 178). It is unknown if these E3s recognize retrotranslocated, 
glycosylated ER-resident proteins that have been missed by the cytoplasmic glycosidase, PNGase, 
which normally removes ER-catalyzed N-glycans prior to ERAD (220, 221). Other E3s connected 
to the ERAD pathway include TRC8, RNF170, RNF185, TRIM13, SMURF1, NIXIN/ZNRF4, 
and NRDP1 (Table 1). One E3, RNF103, is an ER-resident ligase that has yet to be linked to 
substrate degradation. However, the factor regulates protein ubiquitination levels, interacts with 
p97 and DERLIN-1, and is auto-ubiquitinated (182). Once again, this may reflect the dearth of 
characterized, potential ERAD substrates that can arise due to errors in secretory pathway folding. 
1.4.2 The importance of ubiquitin chain extension (E4) and DUB enzymes during ERAD 
For maximal binding to the 26S proteasome, a substrate needs a polyubiquitin chain of at least 
four ubiquitin molecules, but increasing the length beyond four molecules more modestly increases 
proteasome affinity (222, 223). Some recent evidence indicates that the addition of multiple single 
ubiquitin moieties on a proteasomal substrate is sufficient for proteasome targeting (224-226). As 
a result, varying the ubiquitin chain length could regulate degradation efficiency and modify the 
speed at which ubiquitinated substrates are degraded (227). In general, however, the effect of chain 
length on the rate of substrate degradation has not been satisfactorily investigated. But, in order to 
control ubiquitin chain length, cells possess a multitude of factors that either increase (E4s) or 
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decrease (DUBs) the length of the chain. While it is possible the extension of the ubiquitin chain 
is linked to increased degradation, trimming can rescue ubiquitinated substrates or — in some 
cases — facilitate degradation. For instance, if a substrate is deubiquitinated after p97/Cdc48 
activity, it could aggregate in the cytoplasm or might subsequently be re-ubiquitinated by a 
cytoplasmic E3. Alternatively, if a substrate is deubiquitinated prior to p97/Cdc48 activity, it could 
remain in the ER membrane and potentially traffic to the Golgi or be re-ubiquitinated by ER-
resident E3s. These different fates may be dictated by the timing of DUB activity. However, 
deubiquitination prior to p97/Cdc48 activity has also been suggested to allow substrate egress 
through the p97/Cdc48 hexamer (210). Definitive proof of this model awaits the reconstitution and 
structural analysis of p97/Cdc48-dependent degradation. Regardless, of the ERAD-associated 
DUBs, several are associated with p97/Cdc48, whereas others reside in the ER 
membrane/cytoplasm (Table 1). This difference in localization/interaction partners could suggest 
alternative steps at which these DUBs act, but, to date, this has not been satisfactorily addressed.  
The major DUB involved in ERAD in yeast is Otu1. Otu1 was not implicated in ERAD 
until it was shown to interact with Cdc48, which occurs through its ubiquitin regulatory X (UBX)-
like domain (197). Otu1 binding to the N-terminus of Cdc48 does not interfere with binding of the 
Cdc48 cofactors, Npl4 and Ufd1, which are vital to recognize ubiquitinated substrates (228-230). 
These data suggest that different members of the Cdc48 hexameric ring bind Otu1 versus 
Npl4/Ufd1. While Otu1 exhibits deubiquitination activity both in vivo and in vitro, another 
ubiquitin chain modifier, Ufd3, does not appear to catalyze substrate deubiquitination (197). 
However, in ufd3Δ cells, the level of free ubiquitin is significantly decreased (231). The effect on 
free ubiquitin levels may be linked to the Ufd3-binding site on Cdc48, as Cdc48 cannot bind both 
Ufd3 and the E4, Ufd2, at the same time (197). Interestingly, this site is different from the Otu1-
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binding site, as Cdc48 can associate with both the Otu1 and Ufd3 DUBs simultaneously. One view 
is that the binding of Otu1 and Ufd3 to the Cdc48 complex primes this enzyme to inhibit 
ubiquitination, and thus degradation, of ERAD substrates. How this critical step might be further 
regulated is unknown. 
As might be anticipated, there are many more ERAD-associated DUBs in mammalian cells 
than in yeast. YOD1, the mammalian homolog of Otu1, also interacts with p97 through its UBX 
domain (210). YOD1 deubiquitinates known ERAD substrates and associates with DERLIN-1 and 
UBXD8, two components of the HRD1 complex (see above). It was suggested that YOD1 co-
operates with the p97 complex to efficiently retrotranslocate ubiquitinated substrates, which may 
be prevented from being threaded through the central p97 pore (also see above); alternatively, 
YOD1 may act upstream of retrotranslocation by controlling ubiquitin chain length to optimize 
p97 recruitment (210, 232).  
An additional DUB in the mammalian ERAD pathway is ATAXIN-3. ATAXIN-3 
aggregates upon extension of its polyglycine domain, which leads to Machado–Joseph Disease 
(also known as spinocerebellar ataxia type 3) (233). ATAXIN-3 localizes to both the nucleus and 
the cytoplasm, where it interacts with substrate recognition factors for the 26S proteasome (234). 
ATAXIN-3 was subsequently shown to bind p97 through an Arg/Lys-rich region (235, 236). 
Currently, the role that ATAXIN-3 plays in ERAD is not completely clear. Some evidence 
suggests that ATAXIN-3 removes the ubiquitin chain on ERAD substrates to increase protein half-
life, which allows more time for substrate folding (212). An alternative hypothesis is that 
ATAXIN-3 acts after retrotranslocation to support the degradation of ERAD substrates (211). One 
reason for this discrepancy may arise due to differences in methodology, which employed either 
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overexpression studies in vivo or the use of purified complexes in in vitro reactions. Interestingly, 
ATAXIN-3 itself is modified by ubiquitination, which appears to increase DUB activity (237).  
Other mammalian DUBs associated with the ERAD pathway include USP13, USP19, and 
USP25 (Table 1). USP13 interacts with p97, UFD1, NPL4, and UBXD8, and upon USP13 
deletion, cells are more susceptible to ER stress. Moreover, deletion of the gene encoding USP13 
leads to the accumulation of an ERAD substrate, TCRαGFP (205). In another study, USP13 was 
shown to associate with gp78 and deubiquitinate a component of the ERAD complex, keeping the 
complex from becoming inactivated (206). This result is in line with other studies implicating E3 
and DUB activity in regulating the ERAD machinery in addition to or in contrast with the 
modification of ERAD substrates (also see below). In turn, USP19 has seven isoforms that arise 
from alternative splicing. Some of these isoforms contain a C-terminal transmembrane domain, 
which targets them to the ER membrane. The ER membrane-localized population rescues the 
degradation of two ERAD substrates, TCRα and ΔF508 CFTR (207). Interestingly, expression of 
a catalytically inactive USP19 mutant partially rescued TCRα, suggesting a DUB-independent role 
during ERAD. However, Ye and colleagues have provided evidence that the role of USP19 during 
ERAD is dependent on its overexpression (238). Of note, wild-type levels of USP19 are mostly 
cytosolic, lack association with ERAD factors, and fail to alter the degradation of ERAD 
substrates. Finally, USP25, which interacts with p97 as well as HRD1, decreases ubiquitination of 
the ERAD substrate CD3δ (208).  
As mentioned above, a class of E3-like ligases, known as E4s, catalyzes the extension of 
ubiquitin chains. For ERAD, the best characterized member of this family is the yeast protein 
Ufd2. In the absence of Ufd2 activity, the length of ubiquitin chains assembled by the E1–E2–E3 
complex onto a series of ERAD substrates is insufficient for protein turnover both in vitro and in 
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vivo (17). Owing to its interaction with Cdc48, Ufd2 facilitates the degradation of several 
substrates (20). As noted in the previous section, Ufd2 competes with Ufd3 for binding to Cdc48, 
which modulates protein turnover (197). Two mammalian Ufd2 homologs, UBE4A and UBE4B, 
exist, but little is known regarding their role in ERAD. Nevertheless, it has been shown that 
UBE4B can recognize K48 linkages and interact with p97 (239, 240). 
1.5 VARIATIONS ON A THEME 
1.5.1 Alternatives to Lys-48 ubiquitin linkage in ERAD 
While the Lys-48 polyubiquitin linkage is predominantly used for proteasomal degradation, 
polyubiquitin chains appended to other lysine residues are recognized by the 26S proteasome. In 
yeast, ubiquitin chains containing Lys-6, Lys-11, Lys-23, Lys-29, and Lys-33 linkages all 
accumulate to varying levels when the proteasome is inhibited, whereas Lys-63 ubiquitin chain 
levels are unaffected (16). Of the non-Lys-48 polyubiquitin chains, Lys-11-based chains are the 
most affected upon proteasomal inhibition; in addition, only Lys-11 chains increase when Rad23 
and Dsk2 were deleted. Interestingly, the yeast E2, Ubc6, is auto-ubiquitinated with Lys-11 
isopeptide moieties (16); Doa10 and Ubc6 are responsible for a subpopulation of these cellular 
Lys-11 chains (16). Lys-11-linked polyubiquitin chains are also induced upon ER stress (16). 
When similar experiments were performed in mammalian cells, Lys-11, Lys-29, and Lys-48 
linkages rose when the proteasome was inhibited (241). Of these, the majority of the identified 
ubiquitin chain linkages that accumulated were Lys-11 and Lys-48. It is worth noting, however, 
that the accumulation of polyubiquitin moieties containing chains other than those attached via 
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Lys-48 may represent mixed linkages. How these are built and assembled is an area of active 
research (242).  
A mechanism for lysine-independent ubiquitination was first identified with viral E3s. For 
example, the viral E3 ligase, MIR1, promotes the ubiquitination and degradation of a modified 
MHCI that has an artificial glycine/alanine cytoplasmic domain containing only a single cysteine 
(243). Since cysteine is the catalytic residue in E1s, E2s, and some E3s, this residue can clearly 
become ubiquitinated. Alternatively, another viral E3, mK3, can ubiquitinate lysine-less MHCI by 
conjugating ubiquitin to serine and threonine residues (244). Yet another viral protein, the HIV 
protein, VPU, utilizes the SCFβ-TrCP E3 ligase to modify two substrates, tetherin and CD4, by 
utilizing lysine, serine, and threonine (245, 246). Additional evidence obtained investigating the 
ubiquitination of tetherin by SCFβ-TrCP suggested that tyrosine residues in the cytoplasmic 
domain, or the free amino group in the N-terminus, might be targeted (247). Since the exact nature 
of polyubiquitin chains in ERAD substrates is rarely investigated, it is possible that these 
phenomena are actually quite common. In fact, TCRα, which contains only five cytoplasmic 
residues (RLWSS), is modified by HRD1 on the serine side chains (248). HRD1 also modifies 
serines, threonines, and lysines on the immunoglobulin Ns1 LC, which is a trapped ER luminal 
ERAD substrate (152). Moreover, treatment of mini-HC (γ VH–CH1) and NHK α1-antitrypsin 
with sodium hydroxide decreased the amount of ubiquitin appendages, suggesting the presence of 
serine/threonine ubiquitin conjugates on these ERAD substrates. Finally, purified p97 protein 
complexes from cells treated with an ER stressor and a proteasome inhibitor harbored increased 
levels of sodium hydroxide-labile species (152). These data suggest that serine/threonine 
ubiquitination rises during stress, and that this modification plays an important role to mitigate 
cellular stress in vivo.  
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ERAD substrates are not only modified with ubiquitin, but also there is evidence that two 
other protein modifications affect ERAD substrate stability: attachment of NEDD8 and 
SUMOylation. NEDD8 is a ubiquitin-like protein linked to cullins, which activate select E3 ligases 
(249). A role for NEDD8 in ERAD has been suggested for the ERAD substrate ΔF508 CFTR  
(177). During SUMOylation, SUMO (small ubiquitin-like modifier) is conjugated to lysines 
through the action of dedicated SUMO E1, E2, and E3 enzymes in a reaction analogous to the 
ubiquitin-conjugation cascade (250, 251). One difference between the SUMO and ubiquitin 
pathways is that there are three SUMO isoforms in mammals, and only SUMO-2 and SUMO-3 
form chains. 
While SUMOylation is required to regulate numerous cellular events, SUMO tags can also 
recruit an E3, RNF4, which leads to mixed SUMO/ubiquitin chains (252-254). One prominent 
ERAD substrate modified by SUMOylation is CFTR (181). While many E3s facilitate degradation 
of the disease-associated ΔF508 mutant form of CFTR (Table 1), SUMOylation is also evident. 
Specifically, ΔF508 is bound by the small heat-shock protein, HSP27, which recruits the E2 
SUMO-conjugating enzyme, UBC9. The HSP27/UBC9 complex recognizes a non-native fold in 
ΔF508 CFTR, which triggers SUMOylation (255). In turn, the poly-SUMO tag recruits RNF4, 
which poly-ubiquitinates CFTR (181). There is still much more to be explored about this 
modification — and the coordinated interaction and assembly of ubiquitin and SUMO chains — 
and it is likely that a growing number of ERAD substrates will be discovered that are similarly 
SUMOylated. 
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1.5.2 Post-translational modifications on ERAD complexes 
Although this review has focused on protein ubiquitination, Nα-acetylation has also been 
implicated in ERAD, at least in yeast. The importance of Nα-acetylation in ERAD came from a 
screen investigating the nature of the Doa10 complex (123). Based on a genetic screen, nat3Δ 
mutants were found to stabilize a degron, Deg1, which derives from a Doa10-dependent substrate 
known as Mat2α. Nat3 resides in the NatB complex, which is partially responsible for Nα-
acetylation in yeast (256). Importantly, the degradation of this Nα-acetylated population of Deg1 
is also Doa10-dependent (257). However, the NatB requirement for Deg1 degradation was absent 
when wild-type Mat2α was examined (258). Instead, Der1 requires Nα-acetylation and this activity 
is required for ERAD. Without Nα-acetylation, Der1 itself is ubiquitinated by Hrd1 and 
subsequently degraded. 
As suggested in the preceding section, ERAD activity can also be regulated in response to 
cellular stress. For example, the ratio of components in the yeast Hrd1 complex is modified when 
cells are stressed chemically to induce the UPR or by constitutive UPR induction (72). Inactivation 
of the Cdc48 complex similarly leads to altered ratios of Hrd1 complex components, which may 
reflect regulated complex assembly and perhaps increased ERAD efficiency (72). In support of 
this hypothesis, auto-ubiquitination of Hrd1 in vitro is sufficient to recruit the Cdc48 complex, 
which can then engage and retrotranslocate a substrate into the cytosol (92). Surprisingly, Hrd1 is 
also retrotranslocated from the ER in a reconstituted system, suggesting that a Hrd1 regulatory 
factor or a specific modification offsets this destructive event. In mammalian cells, a factor that 
may regulate the Hrd1 complex is the E2, UBE2J1. UBE2J1 activity decreases the levels of Hrd1 
complex members SEL1L, EDEM, and OS-9 (199). Without UBE2J1 activity, ERAD substrates 
were degraded more rapidly than in wild-type cells, which is believed to be due to greater amounts 
and activities of these ERAD-requiring components. Needless to say, numerous other systems 
probably exist to regulate the activity of the ERAD machinery, which must respond to changes in 
cellular stress as well as cellular differentiation and growth in vivo.  
While the examples cited above suggest mechanisms to augment ERAD, negative ERAD 
regulators also exist. ERAD inhibition might allow more time for proteins to fold, perhaps after a 
stress response has been rectified. One negative regulator of ERAD in mammalian cells is the p97 
cofactor SAKS1 (259, 260). SAKS1 interacts with p97 through its UBX domain and also requires 
a functional ubiquitin-associating (UBA) domain to bind polyubiquitin chains (259). When 
SAKS1 binds to both a polyubiquitinated substrate and p97, the degradation of an ERAD substrate 
and a misfolded cytosolic quality control (cytoQC) substrate was attenuated. Another negative 
regulator of ERAD in mammalian cells is the small p97/VCP-interacting protein (SVIP). SVIP 
localizes to the ER membrane, where it binds p97 and DERLIN-1 (261). By associating with p97 
and DERLIN-1, SVIP inhibits the ubiquitination and degradation of select gp78-dependent ERAD 
substrates. These results support the hypothesis that the p97/Cdc48 complex can be regulated by 
competition for cofactor binding. 
1.5.3 Roles for unexpected factors in ERAD     
As a result of the long-term search for factors involved in ERAD through genetic and proteomic 
approaches, it has become increasingly clear that cytosolic factors play important roles in the 
degradation of aberrant proteins in the ER. One such protein is the 26S proteasome-interacting 
E3/E4, Hul5 (30, 262). Hul5 was first shown to be important for the degradation of cytoplasmic 
substrates (263). However, by utilizing fusions of two known ERAD substrates, CPY* and Sec61-
2, to a membrane-tethered product of the LEU2 gene (cytosolic 3-isopropylmalate 
30 
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dehydrogenase), Hul5 was found to facilitate the retrotranslocation of an ER membrane resident 
protein (264). Consistent with its activity as an E4, Hul5 was dispensable for the degradation of 
the CPY* or Sec61-2 portions of the fusion proteins, but instead elongated the ubiquitin chain on 
the transmembrane anchored LEU2 moieties, which increased interaction with the Cdc48 complex. 
In the absence of Cdc48 complex interaction, the ER membrane-anchored LEU2 product was 
stabilized. Furthermore, as discussed earlier in the present study, two E3 ligases that reside in the 
Golgi and inner nuclear membrane, respectively, Rsp5 and the Asi complex, aid in the degradation 
of some substrates. Rsp5 degrades CPY* in a pathway known as Hrd1- independent proteolysis, 
whereas the Asi complex modifies the ER-resident enzyme, Erg11 (145-148). It is unclear if Erg11 
degradation represents a unique aspect of the ERAD pathway or if the Asi complex prevents Erg11 
activity in the nuclear membrane. Overall, cross-talk between components of different cellular 
quality control pathways is important for the degradation of proteins, regardless of substrate 
localization.  
Along with alternative E3s, molecular chaperones localized in the ER and the cytosol are 
implicated in ERAD. However, it is unclear whether these chaperones only serve as recognition 
factors for E3 binding to substrates or if they also serve to bridge the E3 to the substrate. In 
addition, evidence indicates that Hrd1 binds soluble ERAD substrates through its transmembrane 
domains during ubiquitination (92), and the integral membrane ERAD substrate, Hmg2, is 
recognized by Hrd1 transmembrane domains (265). Some cytosolic chaperones help ubiquitinate 
transmembrane ERAD substrates. For example, the yeast Hsp70 (Ssa1) and Hsp40 chaperones 
(Ydj1 and Hlj1) affect the ubiquitination and degradation of several integral membrane substrates 
that display prominent cytoplasmic domains: Ste6* (19, 125), Pma1–D378S (141), and CFTR 
(194, 195). Similar requirements for cytosolic chaperones during ubiquitination were seen in 
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mammalian cells as well (128, 198, 200, 201, 203). Owing to a lack of a requirement for these 
factors in the degradation of ER luminal substrates, it is believed that they do not function in the 
retrotranslocation complex, but instead catalyze ubiquitination and/or proteasome targeting. 
1.6 THESIS SUMMARY 
In this thesis, I aim to address the substrate characteristics that lead to recognition by the ERAD 
machinery.  I also investigate a novel role for a molecular chaperone, the heat shock protein of 104 
kDa (Hsp104), in the degradation of a relatively unstable ERAD substrate.  To this end, I was able 
to demonstrate that an ERAD substrate’s stability is positively correlated to its insolubility.  I was 
also able to demonstrate that Hsp104 is required for the degradation of an insoluble and unstable 
ERAD substrate, Q394X.  Specifically, I demonstrate that Hsp104 acts downstream of substrate 
ubiquitination to disaggregate Q394X at the ER membrane prior to retrotranslocation by the Cdc48 
complex.  While Hsp104 is an AAA+ ATPase, similar to Cdc48, it does not appear to compensate 
for loss of Cdc48 activity, as over-expressing Hsp104 in a cdc48 mutant strain did not rescue 
Q394X degradation.  Finally, I establish that the yeast Hsp110 homologue, Sse1, is required for 
the degradation of Q394X and does not function in the substrate ubiquitination or 
retrotranslocation.  The specific function of Sse1 in the degradation of Q394X will need to be 
addressed in the future.        
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2.0  SUBSTRATE INSOLUBILITY DICTATES HSP104-DEPENDENT 
ENDOPLASMIC RETICULUM ASSOCIATED DEGRADATION 
2.1 INTRODUCTION 
In eukaryotic cells, approximately one-third of all proteins must enter the secretory pathway at the 
endoplasmic reticulum (ER).  After passing quality control checkpoints, properly folded proteins 
proceed through the secretory pathway and are delivered to their ultimate location.  However, 
environmental stressors, genetic mutations, or a stochastic decrease in the efficiency or rate of 
folding leads to the destruction of these nascent proteins via the ER-associated degradation 
(ERAD) pathway (266-268).  To date, numerous factors have been identified that play key roles 
in the recognition, ubiquitination, retrotranslocation, and proteasome-dependent degradation of 
ERAD substrates, and a growing number of ERAD substrates are linked to human diseases (269).   
In contrast to the many ERAD-requiring factors and disease-associated ERAD substrates, 
much less is known about the structural characteristics that result in the recognition of misfolded 
substrates.  Evidence suggests that quality control factors recognize the improper exposure of an 
amphipathic helix (270-272), or other features, such as hydrophobicity (92, 273).  There is also 
evidence that defects in essential post-translational modifications, such as glycosylation, triggers 
the degradation of misfolded substrates (274, 275).  However, due to the limited number and 
diverse nature of the “degrons” used in these studies, it is not yet possible to delineate the rules 
underlying substrate selection.  
  Once an ER-resident protein has been recognized as terminally misfolded, it must be 
ubiquitinated and retrotranslocated from the ER for degradation.  In yeast, ERAD substrates are 
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primarily ubiquitinated by one of the two ER resident E3 ligases, Hrd1 (69, 76) or Doa10 (123, 
140), but more recently the contribution of a cytoplasmic E3, Ubr1, was uncovered (127).  Distinct 
E3 dependencies appear to be due to the localization of the misfolded lesion.  If the lesion occurs 
in the ER membrane (ERAD-M) or in the ER lumen (ERAD-L), the substrate requires the Hrd1 
complex (49, 77, 78, 125).  However, if the lesion resides in the cytoplasmic portion of the protein 
(ERAD-C), the Doa10 complex is required.  Once substrates are ubiquitinated, the Cdc48/p97 
complex is recruited to the substrate, which is then retrotranslocated from the ER and into the 
cytoplasm for degradation by the 26S proteasome (57, 276, 277).  In yeast and most likely in higher 
eukaryotes, soluble substrates within the ER must be retained in an aggregation-free state prior to 
retrotranslocation (278), and in turn specific cytosolic chaperones, most notably Hsp70, Ssa1, and 
Hsp40s, Ydj1 and Hlj1, facilitate the degradation of some ERAD-C substrates (19, 141).  Given 
the diversity of ERAD substrate structures—and the numerous aberrant conformations which they 
might display—an understanding of the rules that govern which chaperones mediate substrate 
selection is in its infancy.  More generally, it has been assumed, but never directly shown, that the 
ERAD machinery preferentially selects aggregation-prone substrates.  
 The handling of integral membrane proteins after retrotranslocation is particularly 
problematic, especially since these aggregation-prone substrates can be found in the cytoplasm in 
yeast and mammalian cells (19, 74, 279-281).  However, a cytoplasmic protein complex was 
identified in mammalian cells that acts as a “holdase” for a subset of retrotranslocated membrane 
substrates.  The central component of this complex is Bag6 (112, 282).  Bag6 complexes with three 
other factors, Ubl4A, TRC35, and SGTA, which also interact with an ER-resident E3, gp78 (113, 
283).  In the absence of SGTA, the ERAD substrate TCRα is stable and the unfolded protein 
response (UPR) is induced, suggesting that this complex plays a general role in ER homeostasis.  
 35 
However, the Bag6 dependence has only been investigated for select substrates, most of which are 
single pass transmembrane proteins.  In addition, yeast lack a Bag6 homolog, indicating that other 
“holdases” for retrotranslocation exist in this organism and that alternate pathways to retain 
aggregation-prone proteins in solution might be at-play in all eukaryotes. 
In this chapter, I have demonstrated that the targeting of a substrate for ERAD is positively 
correlated to its detergent solubility by utilizing a series of truncations within the same protein.  
One of the least soluble truncations, which contains the same degron known to cause the 
degradation of another transmembrane ERAD substrate (284) as well as a cytoplasmic quality 
control substrate (285), was used for the first time to identify the cytoplasmic chaperone, Hsp104, 
as a factor required for ERAD.  Specifically, Hsp104 was determined to be important for the 
disaggregation of this insoluble ERAD substrate in the ER membrane, which allows for efficient 
retrotranslocation by Cdc48.  The identification of this previously undiscovered role for Hsp104 
in ERAD suggests the potential to identify other novel factors that are important for the ERAD of 
misfolded proteins, especially in mammalian cells.   
2.2 MATERIALS AND METHODS 
2.2.1 Yeast strains, plasmids, and plasmid construction 
The S. cerevisiae strains used in this study are listed in Table 1. Solid and liquid drop-out media 
were prepared as described previously (286). Yeast strains and cultures utilized for the Ste6 data 
were grown at 30°C, except for temperature-sensitive strains, which were grown at room 
temperature (25°C) or then shifted to 37°C, as indicated.  Yeast utilized to study the Chimera A 
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truncations were grown at room temperature (23.5°C).  Yeast transformations were performed by 
the lithium acetate method (287).  
A list of the primers and plasmids to create and express the constructs used in this study is 
presented in Table 2.  Plasmids expressing Ste6 truncation mutants were derived from pSM694 
(2µ LEU2 STE6::HA) and contain the triply iterated hemagglutinin (HA) epitope tag between 
amino acids 68 and 69 (the ecto position) in Ste6 (288).  All of the STE6 truncation mutations were 
constructed by homologous recombination in yeast. Briefly, a PCR product containing the desired 
truncation mutation was generated and co-transformed with a linearized gapped version of the 
wild-type STE6 plasmid (pSM694). Plasmids were isolated and sequenced to verify the presence 
of the mutation.   
In order to create the Chimera A truncation series, pCG19 (Guerriero et al, manuscript 
submitted for peer review), which contains two transmembrane regions annealed to the full length 
NBD2 of Ste6, was used as the backbone.  Primer oMP01 was used in combination with oMP02 
through oMP09, resulting in the production of pMP01 through pMP08.  Because pCG19 expresses 
Chimera A with an internal triple HA tag, the resulting pMP01 through pMP08 plasmids are also 
engineered to express triply HA-tagged proteins.  Sequences were verified using DNA sequencing 
services provided by Genewiz (South Plainfield, NJ).  
In order to create pMP13 and pMP14, primers oMP17 and oMP18 were used with oMP19 
to create two forms of the HSP104 over-expression plasmid.  pMP13 expresses HSP104 from the 
endogenous HSP104 promoter in the pRS425 vector (289).  The endogenous promoter was 
inserted by including 350 base pairs upstream of the start site for HSP104 in the insert.  pMP14 
expresses HSP104 from the GPD promoter for constitutive expression in the pRS425 vector.   
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2.2.2 Cycloheximide chase and pulse chase assays  
To determine the effects of C-terminal truncations on Ste6 turnover rates, cycloheximide chase 
analysis was performed as described previously (193) with modifications by Dr. Susan Michaelis 
and Dr. Meredith Metzger.  Briefly, cells were grown to the logarithmic phase in synthetic media 
and 4 OD600 units were harvested, washed, and resuspended to 2 OD600 units per ml in synthetic 
media and incubated at 30°C for 5 min.  Cycloheximide was then added to a final concentration 
of 100 µg/mL to inhibit further protein synthesis.  For the 0 min time point, 500 µL of cells were 
immediately harvested by addition to an equal volume of 2x azide stop mix (20 mM NaN3, 0.5 
mg/ml BSA) on ice.  Cells were incubated during the chase at 30°C.  At each time point after the 
addition of cycloheximide, 500 µL of cells were harvested as above. The cells were then pelleted, 
the supernatant was removed, and pellets were frozen at -80°C until preparation of cell extracts.  
After thawing, the cells were lysed by the addition of a lysis buffer (400mM NaOH, 7% 2-
Mercaptoethanol, 20mM Tris pH8, 20mM EDTA, 1mM PMSF, 2mM leupeptin, and 0.7mM 
pepstatin A) . Proteins were precipitated in 5% trichloroacetic acid (TCA) and protein pellets were 
resuspended in TCA sample buffer (3.5% SDS, 0.5M DTT, 80mM Tris, 8mM EDTA, 15% 
glycerol, 0.1mg/ml bromophenol blue). Proteins were analyzed by 8% SDS-PAGE and 
immunoblotting. HA epitope-tagged proteins were detected using the 12CA5 mouse anti-HA 
monoclonal antibody (Roche Applied Science, Branford, CT) diluted 1:10,000.  Blots were 
visualized using a Versadoc quantitative digital imaging system. Exposures were adjusted to 
approximate equal levels of signal at the 0 min time point and blots were quantified using Quantity 
One software (Bio-Rad Laboratories, Hercules, CA). Half-lives were calculated from exponential 
curve fits using Excel (Microsoft).  
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To determine the effects of C-terminal truncations on the rates of turnover of Chimera A 
and the membrane tethered truncated mutant proteins, cycloheximide chases were performed 
similarly to previously described methods (290).  Briefly, cells were grown to logarithmic phase 
in SC-ura media until cultures grew to an OD600 of 1.0-1.5.  The cultures were then incubated at 
25°C in a water bath for 15 min, with shaking at 160 RPMs.  Cycloheximide was added to a final 
concentration of 200 µg/mL to each culture, and 1.0-1.5 OD600 of cells were harvested at each time 
point and added to sodium azide (final concentration of 17 mM per sample) on ice.  The cells were 
pelleted as above and flash frozen in liquid nitrogen. After all time points were collected, the 
samples were thawed on ice and lysed as above.  Protein pellets were resuspended in trichloroacetic 
acid precipitation (TCAP) sample buffer (80 mM Tris, pH 8, 8 mM EDTA, 3.5% SDS, 15% 
glycerol, 0.08% Tris base, 0.01% bromphenol blue, 5% fresh β-mercaptoethanol) with a 
mechanical pestle for 20 sec and the samples were incubated at 37°C for 30 min.  Next, the 
resuspsended pellets were centrifuged at 18,000 x g for 1 min and a portion of each sample was 
loaded onto denaturing 10% SDS-polyacrylamide gels.  Total proteins were then transferred to 
nitrocellulose using the semi-dry Bio-Rad Trans Blot Turbo for immunoblot analysis.   
To perform immunoblots, the nitrocellulose blots were incubated with a solution 
containing a horseradish peroxidase (HRP)- conjugated primary antibody against the HA-tag 
(Roche Anti-HA-Peroxidase High Affinity (3F10), Rat, 1:5000), and proteins were visualized 
using the SuperSignal Chemiluminescence (Thermo Scientific, Waltham, MA) and subsequently 
imaged on a Bio-Rad Universal Hood II.  To control for potential variability in loading, the blots 
were stripped with 0.1 M glycine, pH 2.2, and then incubated with a rabbit primary antibody 
against the cytoplasmic protein, glucose-6-phosphate-dehydrogenase (G6PDH) (A9521, Sigma-
Aldrich) (1:5000).   Donkey anti-rabbit secondary antibody conjugated to HRP (1:5000, Cell 
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Signaling Technology, Danvers, MA) was then used to visualize G6PDH levels.  The resulting 
signals were quantified using the ImageJ program.     
To determine the dependence of the designated ERAD substrates on the 26S proteasome 
for degradation, BY4742 pdr5Δ (Table 1) cultures expressing pCG19, pCG12, and pMP01 were 
grown as described above.  The 26S proteasome inhibitor, MG132, was added to half of each 
culture to a final concentration of 100 µM.  To the other half of each culture an equal volume of 
DMSO was added.  Cultures were then incubated for 30 min at 25°C.  Next, cycloheximide was 
added to a final concentration of 200 µg/ml and the chase was performed as described above.  To 
analyze the contribution of specific factors to the degradation of Q394X, the designated strains 
were temperature shifted to 37°C for 30 min prior to the addition of cycloheximide and remained 
at 37°C during the chase.  The samples were processed essentially as described above. 
Pulse chase analyses were performed similarly to previously published methods (291).  
Briefly, cultures were grown in SC –ura to an OD600 of 1.0 at 22.5°C.  The cells were then 
concentrated to 3 OD/ml and were labeled with Express 35S (PerkinElmer Life Sciences, 
Bridgeville, PA) for 15 min at 26°C.  The cells were then harvested at 4,500 x g for 3 min, washed 
in SC-ura, and finally resuspended in SC-ura containing methionine, cysteine, and cycloheximinde 
to final concentrations of 13 mM, 40 mM, and 200 µg/ml, respectively.  The cells were collected 
at 0, 15, 30, and 60 min after the addition of cycloheximide and resuspended in 10 mM sodium 
azide on ice.  A total of 1.2 OD600 of cells was collected at each time point.  The cells were 
harvested as above and washed in Buffer 88 (20 mM HEPES, pH 6.8, 150 mM KOAc, 250 mM 
sorbitol, and 5 mM MgOAc) and resuspended in Extract Buffer plus protease inhibitors (50 mM 
Tris-HCl pH 7.4, 1 mM EDTA, 1% SDS, 3mM PMSF, 6 mM leupeptin, and 2.1 mM pepstatin A).  
Glass beads were added to half the volume and the mixture was agitated on a Vortex mixer 4 times 
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for 45 sec with one min on ice between each cycle.  Samples were then heated at 37°C for 10 min 
and centrifuged briefly before 350 µl of immunoprecipitation (IP) wash buffer (50 mM Tris-HCl 
pH 7.4, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, and 0.2% SDS) was added to the samples. 
Next, the mixture were precleared for 3 h at 4°C with 35 µl of a 50/50 slurry of protein A-sepharose 
beads in Protein-A bead resuspension solution (50 mM Tris–HCl pH 7.4, 150 mM NaCl, 5 mM 
EDTA, 1 mM azide).  Samples were then centrifuged briefly, after which the pre-cleared 
supernatants were placed in new 1.5mL Epindorf tubes and incubated overnight at 4°C with an 
anti-HA antibody (Roche, mouse) and 35 µl of the 50/50 slurry of protein A-sepharose beads.  The 
beads were collected by centrifugation and then washed twice each in IP wash buffer and urea IP 
wash buffer, IP wash buffer supplemented with 2M urea, and then once with TAE (50 mM Tris-
HCl pH 7.4, 150 mM NaCl, and 5 mM EDTA).  SDS sample buffer (65 mM Tris-HCl pH 6.8, 5 
mg/mL bromophenol blue, 2% SDS, 1% β-mercaptoethanol, and 10% glycerol) was added to the 
precipitated protein, which was resolved by SDS-PAGE as described above.  Gels were dried and 
exposed to a phosphorfilm for 1-2 days, which was then scanned using a GE Typhoon FLA 7000 
(Boston, MA).  Signals were quantified using ImageJ.                  
2.2.3 Indirect Immunofluorescence 
Samples were prepared similarly to a previously published protocol (292).  Briefly, cultures were 
grown in SC-ura media until reaching an OD600 of 0.5-1.0, and then incubated for 10 min at 22.5°C 
in SC-ura containing 4% formaldehyde.  The cells were resuspended in KM (40 mM KPO4 and 
0.5 mM MgCl2) plus 4% formaldehyde and incubated for 1 h at 30°C.  After collecting the cells 
by centrifugation, they were washed in KM and resuspended in KMS (40 mM KPO4, 0.5 mM 
MgCl2, and 1.2 M sorbitol).  The cell walls were digested with zymolyase 20T (0.5 mg/ml, US 
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Biological, Salem, MA) at 37°C for 20, 25, or 30 min, and the yeast were centrifuged, resuspended 
in KMS, and added to poly-lysine treated slides (ThermoFisher).  The adhered cells were washed 
in ice cold methanol and acetone and then blocked using PBS plus 0.5% BSA, 0.5% ovalbumin, 
0.66% fish-skin gelatin, and 0.1% Triton X-100.  Next, the permeabilized, fixed cells were 
incubated with primary antibodies against the HA tag in the substrates (1:500, Roche) and Kar2 
(1:250) (293).  The samples were washed with blocking solution and incubated with DAPI to 
visualize DNA, along with secondary antibodies Alexa 568 (1:500, goat anti-rabbit, Invitrogen, 
Carlsbad, CA) and Alexa 488 (1:500, goat anti-mouse, Invitrogen, Carlsbad, CA).  Samples were 
mounted using Prolong Gold Antifade Reagent (Molecular Probes, Eugene, OR) and imaged with 
an Olympus FV1000 (Shinjuku, Tokoyo), x100 UPlanSApo oil immersion objective, numerical 
aperture 1.40.   
2.2.4 Determination of substrate solubility  
For detergent solubility assays, 4000-6000 ODs of yeast grown in selective media and expressing 
the designated truncations were harvested.  To determine the solubilities of the Chimera A 
truncation series in BY4742 yeast (Table 1), cultures were incubated at 25°C for 1 h and the cells 
were harvested by centrifugation. Once harvested, yeast ER-enriched microsomes were purified 
using a modified version of a previously described large-scale technique (294).  Here, the cultures 
were resuspended in 100 mM Tris-HCl, pH 9.4, plus 10 mM DTT, and the cells were collected 
and resuspended in lyticase buffer (10 mM Tris-HCl, pH 7.4, 1.5% peptone, 0.75% yeast extract, 
0.7 M sorbitol, and 0.5% glucose).  Roughly 10-20 units of lyticase was added to each culture and 
the solution was incubated at 26°C for 1 h.  The digested cells were then over-layed on an equal 
volume of Cushion 1 (20 mM HEPES, pH 7.4, 0.8 M sucrose, and 1.5% Ficoll 400), and the 
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samples were centrifuged in a Sorvall HB-6 rotor for 10 min at 5800 x g at 4°C.  Pellets were 
resuspended in ice-cold lysis buffer (20 mM HEPES, pH 7.4, 50 mM KOAc, 2 mM EDTA, 0.1 M 
sorbitol, 1 mM of freshly added DTT, 1 mM PMSF, 2 mM leupeptin, and 0.7 mM pepstatin A), 
and lysed using a motor driven Potter-Elvehejm homogenizer (Greiner Scientific Corp, Monroe, 
NC).  The samples were then over-layed onto an equal volume of Cushion 2 (20 mM HEPES, pH 
7.4, 50 mM KOAC, 1 M sucrose, and 1 mM of freshly added DTT) and centrifuged in the HB-6 
rotor for 10 min at 6900 x g at 4°C.  The ER-enriched fraction was removed and centrifuged in a 
Sorvall SS-34 rotor for 10 min at 20,200 x g at 4°C.  The pellet was then washed in Buffer 88 and 
re-centrifuged.  The final pellet was resuspended in Buffer 88 to a final concentration of 10 mg/ml 
as determined spectrophotometrically (A280) in a solution of 1% SDS.      
Solubilization assays were performed by adding 30 µl of Buffer 88, the indicated 
concentration of n-Dodecyl β-D-maltoside, and ER-enriched microsomes to a final concentration 
of 0.5 mg/ml of protein, so the final volume was 31.5 µl.  When designated, these samples also 
contained 6 M urea.  The samples were incubated at room temperature (~22°C) for 30 min and 
then centrifuged for 10 min at 18,000 x g at 4°C. The supernatant was removed and dispensed into 
an Eppendorf tube containing 5x SDS sample buffer. In turn, the pellet was resuspended to an 
equal final volume of 1x sample buffer by pipetting. The samples were then incubated at 37°C for 
30 min followed by a brief centrifugation and subjected to SDS-PAGE and immunoblotting with 
anti-HA as described above. Blots were also incubated in a rabbit polyclonal antisera raised against 
the ER integral membrane protein Sec61 at a 1:1000 dilution (295).  This served as a control for 
microsome solubilization and protein extraction.  The data were analyzed using ImageJ. 
 
 43 
2.2.5 Floatation assays 
To investigate the state of Q394X in the HSP104 and hsp104Δ strains after heat shock, strains 
were transformed with pCG12 and pKN31 and grown in selective media.  A modified version of 
a previously published floatation method was utilized (296).  Briefly, roughly 30 ODs of cells were 
temperature shifted to 37°C for 1.5 hrs, 1 hr of which was in the presence of 100 µM copper sulfate, 
and then collected for 6 min at 4500 rpms in a Thermo Scientific Sorvall ST8 centrifuge.  Pellets 
were resuspended in 200 µL of a lysis buffer (20 mM HEPES, pH 7.4, 50 mM KOAc, 2 mM 
EDTA, 0.1 M sorbitol, 1 mM of freshly added DTT, 20 µM MG132, 10 mM NEM, and 1 x Roche 
Complete EDTA-Free PI cocktail).  Cultures were bead beat 8 times for 30 sec each with 30 sec 
on ice in between cycles.  Samples were pulled off the beads and placed in a fresh 1.5 mL Epindorff 
tube.  Beads were washed with 200 µL of Buffer 88 and collected into the tubes containing the 
samples.  Samples were centrifuged 5 min at 300 x g and 4°C.  170 µL of the supernatant was 
mixed with 630 µL of a 2.3 M sucrose solution in Floatation Buffer (50 mM HEPES pH 7.4, 150 
mM NaCl, 5 mM EDTA, freshly added 1 mM DTT, 1mM PMSF, and 1 x Roche Complete EDTA-
Free PI cocktail).  Gradients were layered from bottom to top with 600 µL of 2.3 M sucrose in 
Floatation Buffer, 800 µL sample (~1.8M sucrose), 1.2 mL of 1.5 M sucrose in Floatation Buffer, 
and 1 mL of 0.25 M Sucrose in Floatation Buffer.  Gradients were centrifuged at 100,000 x g in a 
SW55 TI for 16 hrs at 4°C.  300 µL fractions were taken from the top of the fraction and put in 
fresh 1.5 mL Epindorff tubes.  160 µL of fractions were added to an equal volume of Denaturing 
Buffer (2x TBS pH 7.4, 2% SDS, 8M urea, 20 mM NEM, and 2x Roche Complete EDTA-Free PI 
cocktail) and heated for 30 min at 42°C.  Samples were centrifuged for 5 min at 15,000 x g.  250 
µL of samples were diluted into 1125 µL of Dilution Buffer (1 x TBS pH 7.4, 2% Triton, 10 mM 
EDTA, 0.5% deoxycholate, 10 mM NEM, and 1x Roche Complete EDTA-Free PI cocktail).  40 
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µL of HA-conjugated beads were added to the samples and incubated overnight at 4°C on a rotator.  
TCA was added to the remaining fractions to a final volume of 20% TCA and incubated on ice for 
30 min.  Samples were centrifuged for 20 min at 4°C and 18,000 x g.  Pellets were washed with 
ice old Acetone and centrifuged again.  Supernatants were aspirated and pellets allowed to dry 
briefly.  Pellets were resuspended in 1 x SDS sample buffer by mechanical disruption.  IPs were 
washed 3 x in IP wash buffer, followed by resuspension and brief agitation of the beads in 40 µL 
of TCAP.  IPs and TCA samples were incubated at 37°C for 30 min and centrifuged for 1 min.  IP 
samples were resolved on 7.5% polyacrylamide gels while TCA samples were resolved on 10% 
gels.  Gels were transferred to nitrocellulose as previously described.  TCA samples were blocked 
in TBST + 5% milk at room temperature for 30 min, then incubated with anti-HA antiserum.  IP 
blots were boiled in water for 1 hr, blocked in TBST + 5% milk for 30 min at room temperature, 
then incubated with 1° anti-ubiquitin serum (Sant Cruz, P4D1, Mouse 1:1000) for 1.5 hrs at room 
temperature.  IP blots were washed 3 x 5 min, and then incubated for 1.5 hrs at room temperature 
with 2° anti-mouse HRP-conjugated antiserum (1:5000, Cell Signaling). Both blots were washed 
3 x 5 min in TBST and processed for visualization and quantification as described above. 
2.2.6 in vivo Ubiquitination Assays             
To investigate the role of select factors on the ubiquitination of Q394X, designated strains were 
transformed with pCG12 and pKN31 and grown in selective media.  Briefly, 15 ODs of cells were 
temperature-shifted to 37°C for 1.5 hrs, of which 1 h was in the presence of 100 µM copper sulfate, 
and collected as described above.  Cells were resuspended in 1 mL of RIPA Buffer (10 mM Tris-
Cl pH 8.0, 140 mM NaCl, 1 mM EDTA, 1 % Triton-X100, 0.1% Sodium Deoxycholate, 0.1% 
SDS, 1mM PMSF, 2mM leupeptin, and 0.7mM pepstatin A) and lysed by bead beating 4 times for 
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45 sec each with 1 min on ice between each cycle.  Supernatants were removed and placed in fresh 
1.5 mL Epindorff tubes.  Beads were washed with 500 µL of RIPA buffer, removed, and pooled 
with supernatants.  Samples were centrifuged 3 min at 13,000 rpm and protein levels were 
determined by measuring Abs280nm in 2% SDS.  Equal amounts of total protein were added to be 
immunoprecipated in a final volume of 1 mL.  40 µL of HA-conjugated beads were added to each 
IP sample and incubated over-night at 4°C on a rotator.  IPs were washed, then IP and protein 
samples were resolved and quantified as described above.     
2.2.7 in vitro Ubiquitination Assays 
in vitro ubiquitination conjugation reactions were performed using a variation of a previously 
described method (19) and consisted of 1 mg/ml microsomes purified from the designated strains 
expressing Q394X, 1 mg/mL cytosol, and an ATP regenerating system (1 mM ATP, 40 mM 
creatine phosphate, 0.2 mg/mL creatine phosphokinase in Buffer 88) in a final volume of 40 µl.  
Purified yeast cytosol was prepared using liquid nitrogen via a modified version of a previously 
published technique (294).  After cells were grown at 37°C for 1 h, they were harvested, washed 
in Buffer 88, and flash frozen in liquid nitrogen.  The frozen cells were then lysed using a cold 
mortar and pestle for 1 min in the presence of liquid nitrogen for a total of 6 rounds of grinding.  
Addition of apyrase (0.02 units/reaction) instead of the ATP regenerating system served as a 
negative control. Samples were pre-incubated at room temperature for 10 min and were next 
incubated at room temperature, after 125I-ubiquitin (2.4 x 106 cpm/rxn) was added to a final 
concentration of 1.5 mg/ml ubiquitin.  The samples were then incubated at 37°C for 45 min before 
125 µl of a 1.25% SDS Stop solution (50 mM Tris–Cl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 
1.25% sodium dodecyl sulfate (SDS), 1 mM PMSF, 2 mM leupeptin, 0.7 mM pepstatin A, and 10 
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mM N-ethylmaleimide (NEM)) was added to the reactions and incubated at 37°C for 30 min.  A 
total of 400 µl of a Triton solution (50 mM Tris–Cl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 2% 
Triton X-100, 1 mM PMSF, 2 mM leupeptin, 0.7 mM pepstatin A, and 10 mM NEM), 35 µl of a 
50/50 protein A-sepharose slurry in Protein A bead resuspension solution, and anti-HA antibody 
were then added to each reaction and samples were immunoprecipitated overnight at 4°C on a 
rotator.  After centrifugation, the pellets were washed 3 times in an IP wash buffer, and after all 
fluid was removed from the beads, TCAP sample buffer was added, the samples were briefly 
agitated, and incubated at 37°C for 30 min.  The precipitated chimeras were then resolved on 
duplicate 10% SDS-polyacrylamide gels.  One gel was transferred to nitrocellulose and incubated 
with anti-HA-HRP antibody to control for IP levels.  The second gel was washed in ddH2O, placed 
on filter paper, and dried.  Dried gels were then exposed to a phosphorfilm for 2-3 d.  Imaging and 
quantification were performed as described above.     
2.2.8 Live cell imaging 
Yeast strains lacking the PDR5 gene and expressing an integrated, C-terminal GFP-tagged copy 
of Hsp104 were transformed with either the Q394X or an empty expression vector control.  
Overnight cultures were grown in SC –ura media and diluted to early log phase the next day. At 
that time, MatTek (Ashland, MA) glass bottom microwell dishes were treated with 1 mg/mL 
concanavalin A (ConA) and allowed to dry at 22°C for 1.5 hrs.  After the cells doubled twice, the 
cultures were treated with either DMSO or a final concentration of 10 µM of MG132 and 
immediately placed in wells in the MatTek dishes.  The dishes were then placed on a temperature 
controlled stage set to 45.7°C, which was required to shift the cells to 37°C.  Cells were imaged 
from multiple sections of the plate every 5 min for 1 hr.  Images were taken on a point scanning 
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Nikon A1 confocal (Chiyoda, Japan).  The objective was a 1.40 NA 100x and images were taken 
at a half frame per second, averaging two frames per image. 
2.3 RESULTS 
2.3.1 Select Truncations in an NBD Lead to Decreased Protein Stability 
A C-terminal 42 amino acid truncation in the yeast ATP-binding cassette (ABC) transporter, Ste6, 
leads to the selection of this yeast plasma membrane protein for ERAD (284).  The destabilizing 
truncation resides in the cytoplasmic second nucleotide binding domain (NBD2) of Ste6 (black 
arrow, Figure 4A).  This ERAD substrate is known as Ste6*, and many of the requirements for the 
degradation of this protein, referred to here as “Q1249X”, have been characterized (19, 125, 284).  
Because the truncation in Ste6* was identified in a genetic screen, Drs. Meredith Metzger and 
Susan Michaelis from the Johns Hopkins School of Medicine wished to determine why this 
mutation destabilizes Ste6.  To this end, they introduced a series of truncations into NBD2 both 
N- and C-terminal of Q1249.  In cycloheximide chase analyses, most of the truncated proteins 
immediately N-terminal and C-terminal to Q1249 were similarly unstable.  In contrast, a modest 
C-terminal truncation (R1268X) and, surprisingly, a more severe truncation upstream of Q1249 
(L1240X) were as stable as the wild type protein (Figure 4B-C).   
To investigate the mechanism underlying the recognition and degradation of these 
truncated species in a more simplified system—one in which the potential contribution of Ste6’s  
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Figure 4. The metabolic stability of Ste6 containing truncations in the second nucleotide 
binding domain is highly variable 
(A) Schematic of the yeast 12-transmembrane a-factor transporter, Ste6, with the relative site of 
the Q1249 truncation (“Ste6*”) marked by an arrow. (B) Metabolic stabilities were determined by 
Drs. Meredith Metzger and Susan Michaelis from the Johns Hopkins School of Medicine by 
cycloheximide chase analysis and proteins were visualized by immunoblotting with an anti-HA 
antibody; t1/2 indicates approximate half-life of each protein. (C) A bar graph depicting the relative 
half-lives of the Ste6 truncations. 
 
12 transmembrane domains during ERAD might be lessened—NBD2 was tethered to the ER by 
introducing a hydrophobic hairpin at the N-terminus.  Into the resulting chimera, “Chimera A”, I 
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then introduced the analogous Ste6 truncations.  As anticipated, the truncation analogous to 
Q1249X/Ste6* (Q394X) was unstable, as were substrates truncated near this site.  Similar to the 
results with the most severe and shortest truncations in Ste6, the L385X and R413X truncations in 
Chimera A were as stable as the wild type protein (Figure 5B-C).  To ensure that differences in 
the half-lives were not an artifact of the method, I also determined the half-life of Chimera A and 
Q394X by pulse chase analysis, and the turnover rates of these substrates were similar to what was 
observed in the cycloheximide chase assays (Figure 5D).  These data indicate that the Chimera A 
truncation series provides a unique opportunity to investigate how the ERAD machinery 
distinguishes between a stable and an unstable substrate that are identical but differ only by the 
presence/absence of 2 amino acids (i.e., L385X and M387X).    
To offer a glimpse of the potential structures adopted by these truncation mutants, Dr. 
Chris Guerriero from the University of Pittsburgh Department of Biological Sciences created a 
homology model for NBD2 from Ste6 based on the structure of murine P- glycoprotein, from 
which his analysis suggested was the ideal model protein to create a homology model (Figure 6).  
Subsequent homology models from Phyre2 (297) and Uniprot (www.uniprot.org) produced 
homology models similar to Dr. Guerriero’s model from the murine P-glycoprotein.  Each of the 
destabilizing truncations occur within a βαβ turn, while the stable mutated proteins have 
truncations at either the beginning (L1240X/L385X) or end (R1268X/R413X) of this structural 
motif.  These results suggest that disrupting, but not deleting this secondary structure increases 
protein turnover.  I further predict the destabilizing mutations give rise to unaccommodated β 
strands, which might be aggregation-prone. 
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Figure 5. The metabolic stabilities of Chimera A truncation mutants reflects the half-lives 
of the analogous Ste6 truncation mutants 
(A) Schematic of the yeast dual pass transmembrane protein, Chimera A, with the relative site of 
the Q394 truncation marked by an arrow. Chimera A consists of the first transmembrane domain 
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of Ste6 followed by a second poly Ala/Leu transmembrane domain annealed to NBD2 from 
Ste6.  (B) Metabolic stabilities were determined by cycloheximide chase analyses and proteins 
were visualized by immunoblotting with an anti-HA antibody. (C) A bar graph depicts the 
relative half-lives of the Chimera A truncations. (D) The relative half-lives of Chimera A and 
Q394X by cycloheximide chase analysis were compared to the Chimera A and Q394X half-lives 
by pulse-chase analysis. For pulse chase analyses, cells were pulsed for 15 min with 35S-Met, 
then chased for 1 hr.  Cells were lysed and the substrates were immunoprecipitated with an anti-
HA antibody and Protein A-Sepharose.  Representative images from each condition are shown, 
but a total of 6 (for cycloheximide chase analyses) and 7 (for pulse chase analyses) independent 
experiments were performed and the data were averaged for t1/2 calculations. 
 
2.3.2 The Rate of Degradation for the ER-Membrane Resident Chimera A Truncation 
Series by ERAD Correlates with their Solubility 
To ensure that the Chimera A truncated mutants are ERAD substrates, I confirmed that two 
of the more stable (Chimera A and L385X) and the less stable (Q394X) substrates localize to the 
ER (Figure 7A), and their degradation is proteasome-dependent since treatment with the 26S 
proteasome inhibitor, MG132, slows their turnover by ~2-3-fold (Chimera A and L385X) or ~7 
fold (Q394X) (Figure 7B).  In contrast, there appears to be no dependence on the vacuole for 
degradation (Guerriero et al, manuscript submitted for peer review).  These results, along with 
degradation being Hrd1 and Doa10-dependent (Figure 7C), demonstrates that the Chimera A 
derivatives are ERAD substrates..  It is important to note that I failed to observe complete substrate 
stabilization with either proteasome inhibition or the deletion of HRD1 and DOA10.   The lack of 
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complete dependence on the proteasome may arise because MG132 is known to only inhibit the 
chymotrypsin activity of the 26S proteasome, leaving two 26S proteasome activities intact (298).  
It is also possible that the drug had decreasing stability over time, leading to varying levels of 
proteasome inhibition throughout the chase.  For the incomplete dependence of Q394X 
degradation on Hrd1 and Doa10, work in our lab has shown that Q394X is not degraded by the 
vacuole (Guerriero et al, submitted for peer review).  However, other labs have identified 
alternative E3 ligases that act during ERAD, such as the cytosolic E3, Ubr1 (127), as well as 
several other known E3s (see Table 1).  Therefore, compensation by other E3s could also be 
responsible for the lack of complete stabilization of Q394X in the absence of Hrd1 and Doa10.         
I next asked why the truncation mutants fit into two groups: those that are more vs. less 
stable.  Based on a previous analysis of individual ERAD substrates, there is some evidence that 
substrate insolubility is associated with protein recognition and degradation by ERAD (92, 273).  
To address whether members of the Chimera A truncation series exhibit different solubilities, I 
prepared ER-enriched microsomes from strains expressing each protein and then measured their 
solubilities after treatment with dodecyl maltoside (DDM) and centrifugation.  DDM was initially 
chosen for two reasons: 1) the hydrophilic-lipophilic balance (HLB) for DDM is in the optimal 
range of a surfactant for membrane protein solubilization (299, 300) and 2) DDM was determined 
to be an optimal non-ionic detergent to solubilize membrane proteins over others, such as Triton-
X-100 (301).  To confirm that DDM was the detergent I would use in my solubility assays, I tested 
the solubility of Q394X in the presence of a variety of other non-ionic detergents, including octyl 
glucoside, digitonin, and Triton-X100.  I determined that none of these were able to improve the 
solubility of Q394X over what I observed with DDM (data not shown). 
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Utilizing this assay, I was able to determine that the Chimera A truncations exhibit varying 
solubilities in DDM (Figure 8).  Strikingly, there is a positive correlation between substrate 
stability and detergent solubility (Figure 9A).  As a control for this experiment, I also examined 
the solubility of the ER-membrane protein, Sec61, in the samples (Figure 8).  I consistently see 
similar levels of solubilization of Sec61 in our assays, suggesting that the difference in   insolubility 
between the mutants is not likely to be due to varying levels of membrane disruption.  I also found 
that Q394X solubility in the presence of DDM is significantly increased by urea, such that the 
amount of Q394X in the supernatant (“S”) now equals the amount seen when the solubility of the 
more stable Chimera A species is examined under identical conditions (Figure 9B). These 
combined results strongly suggest that ERAD substrate selection can depend on a measureable 
biochemical parameter, one that takes into account the protein’s aggregation-propensity in vitro.   
Moreover, the ability of urea to augment the solubility of an ERAD substrate so it becomes more 
“wild type” suggests a potential role for chaperones to prevent aggregation of the substrate. 
2.3.3 Hsp104 is Required to Degrade a Poorly Soluble ERAD Substrate 
Cytosolic molecular chaperones play important roles in the ERAD of integral membrane proteins 
(141, 194), including Ste6*(125).  To define whether the same cytosolic chaperones are required 
to facilitate Q394X degradation, I utilized strains expressing Q394X in which the genes 
corresponding to each chaperone were either deleted or mutated.  Similar to what was observed 
with Ste6* (125), both the cytosolic Hsp70, Ssa1 (Figure 10A), and the cytosolic Hsp40, Ydj1 
(Figure 10B) contribute to Q394X degradation.  These chaperones were previously shown to 
augment Ste6* ubiquitination (19), but based on the relative insolubility of this substrate, as well 
as the fact that Ssa1 and Ydj1 function with Sse1 in a disaggregation complex (302, 303), I 
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measured Q394X turnover in a strain lacking Sse1.  As shown in Figure 10C, Q394X was 
stabilized in sse1Δ yeast. Based on the fact that these chaperones act as disaggregases, and can 
work in conjunction with a dedicated protein disaggregase in yeast, Hsp104 (48, 304, 305), I next  
investigated the role of Hsp104 in the degradation of Q394X.  Although significant stabilization 
of an ERAD substrate has never been observed in an hsp104Δ mutant, I observed strong 
stabilization of Q394X in the hsp104Δ strain.  Moreover, when a multicopy plasmid was 
introduced into a strain containing HSP104 driven from its native promoter, Q394X degradation 
was accelerated (Figure 10D, solid triangles).  I did not observe a similar dependence on Hsp104 
for the degradation of Ste6* (Figure 11), suggesting that there are some potential differences in 
the recognition and clearance of Ste6* vs Q394X by ERAD (for more details, see Discussion).  
Similar to our observations for E3 dependence, we also did not see 100% stabilization of Q394X 
degradation in our mutant yeast.  This could be explained by compensation by other 
chaperones/incomplete inactivation of the temperature sensitive mutants.  
Because some chaperones are required for substrate ubiquitination during ERAD, such as 
Ssa1 and Ydj1 (19, 141), I next asked if Hsp104 and Sse1 also facilitate Q394X ubiquitination.  
To measure substrate ubiquitination, I expressed Q394X in HSP104, hsp104Δ, SSE1, and sse1Δ 
strains that also expressed myc-tagged ubiquitin. After the substrate was immunoprecipitated, I 
found that Q394X ubiquitination was not affected by the loss of Hsp104 function (Figure 12).  As 
a control, I found that Q394X ubiquitination—like Ste6* ubiquitination (19)—was blunted when 
Ssa1 was inactivated at the non-permissive temperature in the ssa1-45 yeast strain.  Together, these 
data indicate that Hsp104 plays a previously unknown role during ERAD, one that functions 
downstream of substrate ubiquitination. 
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Figure 6. The truncation sites in the second nucleotide binding domain (NBD2) reside 
within a predicted β-sheet  
A structure for the closest homologous domain was selected by querying the Research 
Collaboratory for Structural Bioinformatics Protein Data Bank, www.rcsb.org (306). The mouse 
P-glycoprotein (PDB ID: 4M1M, (307)) was chosen based on 35% sequence identity in the NBD2 
sequence. Homology models were then constructed with Moddeller 9v13 (308). Shown here is the 
predicted model of the cytosolic NBD in the absence of its TM domains.  A magnified view of the 
region containing the truncations in the Ste6 and Chimera A NBD2 is shown (amino acids 1240-
1268 in Ste6).  The structure and predicted sites of each truncation were visualized using PyMOL 
(The PyMOL Molecular Graphics System, Version 1.7.4.5 Schrödinger, LLC.). Shown in red is 
the C-terminus of the NBD2.  Sites labeled in blue demonstrate similar half-lives to the wildtype 
protein while those labeled in orange are degraded more quickly. 
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Figure 7. Chimera A truncations are localized to the ER and are degraded by ERAD 
(A) The cellular localization of Chimera A, Q394X, and L385X were determined by indirect 
immunofluorescence microscopy.  Each truncation was detected with anti-HA antibody, anti-Kar2 
antiserum was used to mark the ER, and the nucleus was visualized with DAPI.  (B) Yeast strains 
lacking PDR5 and expressing either Chimera A, Q394X, or L385X were treated with DMSO 
C 
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(closed circles) or 100 µM MG132 (open circles) for 30 min prior to a cycloheximide chase 
analysis performed at 26°C. Data represent the means of N = 9 (L385X) or N = 12 (Chimera A 
and Q394X) independent experiments, +/- SEM; Chimera A, P < 0.001 for all time points, Q394X, 
P < 0.01 for all time points, L385X, P < 0.001 at the 30 and 60 min time points, for data ±MG132. 
(C) Cycloheximide chase analyses were performed at 26C for Q394X to determine the requirement 
for two canonical ERAD E3s, Hrd1 and Doa10.  N = 3-6 independent experiments, +/- SEM.   
 
 
In addition to Hsp104, other chaperones are known to prevent protein aggregation, and 
some of these also function with Hsp104.  Therefore, I measured Q394X degradation in yeast 
lacking the small heat shock proteins (sHSP), as they help to facilitate substrate disaggregation by 
Hsp104 (48, 309), as well as in strains containing a temperature-sensitive mutation in the TriC 
complex or in yeast deleted for SGT2, which encodes the yeast homolog of a “holdase” that 
functions during the retrotranslocation of ERAD substrates in mammals  (48, 283, 310, 311).  In 
addition, the yeast homologue of UBIQUILLIN, called Dsk2, was investigated for a role in Q394X 
degradation, as UBIQUILLIN plays an important role in the degradation of known ERAD 
substrates (110).  As shown in Figure 13, the degradation of Q394X was unaffected in any of these 
strains, suggesting that Hsp104 is a dedicated chaperone during the ERAD of this new model 
substrate.  
2.3.4    Q394X aggregates in the ER membrane in the absence of Hsp104 function 
Because Hsp104 is important for the degradation of Q394X (Figure 10D) and acts at some point 
downstream of Q394X ubiquitination (Figure 12), I hypothesized that Hsp104 plays a role in the 
 59 
disaggregation of Q394X prior to degradation.  In order to test this hypothesis, I utilized a modified 
flotation assay (296).  In the absence of Hsp104 at high temperatures, a population of Q394X shifts 
to a heavier fraction (Figure 14B, Fraction 7, HSP104 vs hsp104Δ).  This population of Q394X 
that shifts to a heavier fraction in the absence of Hsp104 is also poly-ubiquitinated, suggesting it 
has been selected for ERAD (Figure 14C, Fraction 7, HSP104 vs hsp104Δ).  To control for any 
variation in fraction removal and to determine if this heavier population of Q394X in the hsp104Δ 
samples is still localized to the ER, I compared the location of Sec61 between the HSP104 and 
hsp104Δ (Figure 14D).  Indeed, there appears to be no significant difference in the location of 
Sec61 between the HSP104 and hsp104Δ samples (Fractions 3-7), suggesting this shift in Q394X 
density is due to the absence of Hsp104 function.  While a majority of the Sec61 appears to be 
present in fractions 3-6, there is roughly 5-10% of the Sec61 in fraction 7, where I see the increase 
of Q394X residence in the hsp104Δ samples.  These results, along with the localization of Hsp104-
GFP to puncta when temperature-shifted cells express Q394X (Figure14), suggest that Hsp104 
acts to reduce Q394X aggregation, potentially at the ER-membrane.   
Since I know that Hsp104 acts downstream of Q394X ubiquitination (Figure 12), I next 
investigated the role of Hsp104 in Q394X retrotranslocation from the ER.  Using a previously 
established in vitro retrotranslocation assay from our lab (19), I discovered that ubiquitinated  
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Figure 8. The Chimera A truncation mutants display varying levels of detergent solubility 
BY4742 (wild type) yeast expressing the indicated truncations were harvested and ER-enriched 
microsomes were prepared as described in the Experimental Procedures.  The microsomes were 
then treated with 1.8 mM DDM to solubilize the substrates.  As controls, reactions were conducted 
in the absence of detergent (“0 mM”) or in the presence of the strong, ionic detergent sodium 
dodecyl sulfate (SDS).  Samples were centrifuged at 18,000 x g and the percent of solubilized (S) 
and membrane-retained (P) protein was determined by immunoblotting with an anti-HA antibody.  
These values are reported in Figure 3C.  Sec61 solubilization was also monitored by use of an anti-
Sec61 antibody to control for variations in membrane solubilization between samples. The images 
are representative for N = 4 independent experiments. 
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Figure 9. The half-lives of the Chimera A truncations correlates with detergent solubility 
(A) The metabolic stabilities of the truncation mutants were determined by cycloheximide chase 
analyses at 26°C and protein solubilities were determined by the percent of soluble substrate after 
ER-derived microsomes were treated with 1.8 mM of the non-ionic detergent, dodecyl-maltoside 
(DDM) and the mixture was centrifuged at 18,000 x g.  Data represent the means of N = 4-6 
independent experiments for stability measurements and N = 4 independent determinations for 
protein solubility. (B) Wild type (BY4742) microsomes containing Q394X were treated with 0.6 
mM DDM alone or 0.6 mM DDM in the presence of 6 M urea and protein residence in the 
supernatant (S) and pellet (P) fractions was analyzed after centrifugation and immunoblotting.  
Sec61 was used as a control for membrane solubilization. 
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Q394X is less efficiently retrotranslocated in the absence of Hsp104 function (Figure16B, 
Supernatant (“S”) lanes as a percentage of the total ubiquitinated signal for HSP104 vs hsp104Δ). 
In this experiment, the supernatant was defined as the soluble fraction after an 18,000 x g 
centrifugation step.  I observed the same ratios of retrotranslocated, ubiquitinated Q394X in both  
the HSP104 and hsp104Δ reactions after a 100,000 x g centrifugation step, suggesting the 
retrotranslocated protein is soluble and not in a partially aggregated state (Figure 16C).  
Interestingly, there is a high molecular weight population of ubiquitinated Q394X that is present 
when using components purified from hsp104Δ cells, but not from the HSP104 cells (Figure 16 B-
C, asterisk).  Components purified from strains lacking the sHsps, which do not play a role in 
Q394X degradation (Figure 13A), did not significantly alter the retrotranslocation of ubiquitinated 
Q394X (Figure 17).  Interestingly, while Sse1 does play an important role in Q394X degradation, 
it does not appear to play a significant role in the retrotranslocation of Q394X (Figure17).  This 
result, along with a minimal change in Q394X ubiquitination when Sse1 is absent (Figure 12), 
suggests that Sse1 may act at some point after Q394X is retrotranslocated from the ER.   The 
decrease in the efficiency of Q394X retrotranslocation in the absence of Hsp104 function, along 
with the shift of Q394X in the hsp104Δ strain to a denser, ER-localized (Sec61-containing) fraction 
led me to ask whether Hsp104 acts on aggregated Q394X in the ER membrane prior to 
retrotranslocation or on aggregated Q394X that has already been retrotranslocated.  To address 
this question, the Q394X-containing pellets were washed in urea and recollected at 18,000 x g.  I 
found that negligible amounts of ubiquitinated Q394X were solubilized by urea in reactions both 
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Figure 10. The degradation of an unstable/poorly soluble substrate, Q394X, requires select 
cytoplasmic chaperones 
The stabilities of Q394X in the indicated wildtype and mutant strains were determined by 
cycloheximide chase analyses at 37°C. (A) The yeast cytosolic Hsp70, Ssa1; N = 6 independent 
experiments, +/- SEM. (B) The yeast cytosolic Hsp40, Ydj1; N = 6 independent experiments, +/- 
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SEM. (C) The yeast cytosolic Hsp110, Sse1; N = 3 independent experiments, +/- SEM. (D)  The 
yeast cytosolic disaggregase, Hsp104; N = 3-6 independent experiments, +/- SEM, P < 0.01 for 
time points 15 min and 30 min for hsp104Δ vs HSP104.  For HSP104 OE, P < 0.05 at time point 
15 min for HSP104 vs HSP104 OE is an Hsp104 overexpression strain.  In all panels, *P < 0.05, 
**P < 0.01, ***P < 0.001.  
 
 
Figure 11. Hsp104 is not required for the degradation of Ste6* 
The stability of Ste6* in the absence of Hsp104 function was determined by cycloheximide chase 
analyses at 37°C. N = 3 independent experiments, +/- SEM. 
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Figure 12. Hsp104 acts downstream of Q394X ubiquitination 
Q394X ubiquitination was examined in the indicated yeast strains after cells were shifted to 37°C 
for 1.5 hrs, lysed, and the substrate was immunoprecipitated using anti-HA-conjugated agarose 
beads.  Q394X was detected (HA) as well as total ubiquitin. The percent of in vivo ubiquitination 
was calculated after ubiquitination levels were first normalized against Q394X protein levels 
(Ubiquitin/HA), with the signal in the wild type strains set to 100%. Data represent the means of 
N = 3 (SSE1 and sse1Δ), N = 4 (HSP104, SSA1, and ssa1-45), and N = 5 (hsp104Δ) independent 
experiments, +/- SEM; ***P < 0.001. 
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in the presence and absence of Hsp104 (Figure 19A, “US” lanes).  As a control for this experiment, 
we found that Cdc48 and Hsp104 were completely released from the microsome membrane after 
treatment with urea, while a population of Sec61 and Q394X remained in the ER membrane 
(Figure 19B).  This result suggests that Q394X residing in the pellet has not already been 
retrotranslocated.  Based on these results, one could hypothesize that Hsp104 acts to 
retrotranslocate ubiquitinated Q394X into the cytosol.   However, over-expression of Hsp104 in a 
cdc48 mutant strain did not rescue Q394X degradation (Figure 20).  Therefore, I believe that 
Hsp104 acts on aggregated, ubiquitinated Q394X in the ER membrane prior to retrotranslocation 
by Cdc48 (Figure 21). 
2.4 DISCUSSION 
The process of ERAD has been linked to multiple human diseases and, as a result, has been heavily 
studied (269).   While much has been discovered about the process of ERAD, one area that has 
been difficult to address is why substrates are recognized as being misfolded and degraded by 
ERAD.  Interestingly, Dr. Meredith Metzger and Dr. Susan Michaelis (Johns Hopkins University, 
Baltimore, MD) found that truncations in the yeast ABC transporter, Ste6, starting at the C-
terminus were not sufficient to increase the extent of the degradation of the mutant Ste6 protein.  
This effect is the opposite of what has been demonstrated for another plasma membrane ATPase, 
Pma1, where truncating further from the C-terminus led to increased protein degradation (312).  
Utilizing a homology model of the Ste6 NBD2 made by Dr. Christopher Guerriero against the 
 
 
 68 
 
  
Figure 13. The ERAD of Q394X is unaffected by the small heat shock proteins, the TriC 
complex, a component of the Tail-Anchor insertion complex, or the Rad23-Dsk2 Ubl/Uba-
domain containing proteins 
All cycloheximide chases were performed at 37°C with a 30 min pre-shift at 37°C.  The stability 
of Q394X was investigated in the absence of (A) the small heat shock proteins, Hsp26 and Hsp42 
(N = 3), (B) the activity of a chaperonin subunit, Cct1 (N = 16), (C) the Tail-Anchor insertion 
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pathway component, Sgt2 (N = 6), and (D) the 26S proteasome-associated factors, Rad23 and 
Dsk2 (N = 6).  All data represent the means of the indicated number of independent experiments, 
+/- SEM. 
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Figure 14. Hsp104 is required to disaggregate ubiquitinated Q394X 
(A) A schematic of the flotation assay used to determine substrate oligomerization.  Cell lysates 
from HSP104 or hsp104Δ cells expressing the Q394X mutant treated at 37°C for 1.5 hrs were 
prepared and analyzed by equilibrium sucrose density centrifugation.  Proteins in each fraction 
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were TCA precipitated and immunoblotted with anti-HA antibody to detect (B) Q394X, or (C) 
were denatured and immunoprecipitated to detect ubiquitinated Q394X.  (D) The migration of 
Sec61 was used to identify the migration of the ER. Data represent the means of N = 4-5 
independent experiments +/- SEM; * P < 0.05.   
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Figure 15.  GFP-tagged Hsp104 localizes to puncta when temperature-shifted cells express 
Q394X 
Yeast strains lacking PDR5 and containing an integrated HSP104-GFP were utilized to monitor 
Hsp104 localization under conditions where Hsp104 is required for Q394X degradation.  
Specifically, cells expressing either an empty expression vector (EV) or the insoluble mutant, 
Q394X, were incubated at 37°C and treated with DMSO or the proteasome inhibitor, MG132.       
 
published structure of the murine P-glycoprotein, another ABC transporter, I hypothesize that 
these truncations disrupt a predicted β-sheet.  In fact, alterations and improper folding of β-sheet 
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rich proteins is well known to cause a multitude of human diseases linked to protein aggregation 
(51, 313).  Therefore, further investigation into why these truncation mutants are processed 
differently could contribute important information to better understand ERAD substrate selection.  
To simplify our system, I then introduced the analogous Ste6 truncations in a model ERAD 
substrate, called Chimera A.  I demonstrated that the analogous truncations in Chimera A have 
similar trends in the measured metabolic stabilities as their Ste6 counterparts.  This new system 
allowed me to investigate the characteristics responsible for substrate selection by ERAD without 
complications due to complex intradomain interactions.   
Next, I utilized the Chimera A truncations to address why select members of my truncation 
series exhibited shorter metabolic stabilities than others.  It is important to point out that the NBD2 
of Ste6 has a predicted amphipathic helix (123).  However, this predicted amphipathic helix is over 
100 amino acids away from the region where the truncations reside.  Based on Dr. Christopher 
Guerriero’s homology model, it does not seem likely that these two regions interact.  Therefore, I 
chose to investigate whether the Chimera A truncation mutants exhibit varying solubilities, which 
is another substrate characteristic hypothesized to lead to selection for ERAD (92, 273).  For 
example, Gilon et al. (1998) found that fusing the C-terminus of two proteins to specific peptides 
led to decreased protein stability.  Furthermore, these proteins developed a dependence on two E2s 
known to be important in ERAD: Ubc6 and Ubc7 (60, 122). It was determined that these peptides 
were highly hydrophobic.  However, this finding was discovered by fusing synthetic peptides to 
the C-termini of a protein.  The peptides are not a native part of the proteins and could disrupt 
overall secondary structure and induce alternative interactions with cellular components.  In 
addition, Stein et al. (2014) showed that a more aggregation-prone version of the ERAD substrate, 
CPY*, had a higher binding affinity than CPY* to Hrd1, which plays a role in ERAD. 
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Figure 16. Loss of Hsp104 function leads to a decrease in the amount of soluble, 
ubiquitinated Q394X 
(A) A schematic of the in vitro ubiquitination/retrotranslocation assay.  (B,C) in vitro 
ubiquitination assays utilizing an 18,000 x g (B) or 100,000 x g (C) centrifugation step were 
utilized to collect retrotranslocated Q394X. Ubiquitinated Q394X was immunoprecipitated from 
the retrotranslocated supernatant (S) fractions and the membrane bound pellet (P) fractions after 
immunoprecipitation.  Reactions were run in the presence of either wild type (HSP104) or 
hsp104Δ cytosol, and in the presence or absence of ATP, as indicated. The native molecular 
weight (arrow) and high molecular weight species (asterisk) of Q394X are marked. 
 
While important, this was shown using purified components in reactions in which Hrd1 had been 
immobilized and used at high concentrations. 
Utilizing my Chimera A truncation series, I demonstrated a positive correlation between 
substrate solubility and substrate stability.  Importantly, I was able to show that this difference in 
solubility within the Chimera A truncation series is not due to variations in membrane extraction; 
the solubility of a less soluble Chimera A mutant is able to be rescued by the addition of urea.  
For the first time, by using a series of mutations within the same protein, I was able to positively 
correlate the stability and solubility of an ERAD substrate.  This correlation between solubility 
and stability is further supported by evidence from Arteaga and colleagues (271).  While the 
authors concluded that the exposure of an amphipathic helix was the deciding factor for ERAD 
substrate selection, they also determined that the hydrophobicity of a predicted amphipathic helix 
was crucial for substrate selection and degradation. Because they never determined the 
solubilities of their substrates, it is possible that the exposure of the hydrophobic residues within  
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Figure 17. The retrotranslocation of ubiquitinated Q394X is unaffected by the small heat 
shock proteins 
(A) In vitro ubiquitination assays were performed with cytosol and microsomes isolated from 
HSP26 HSP42 and hsp26Δ hsp42Δ strains.  (B) Quantification of the percentage of 
retrotranslocated, ubiquitinated Q394X is present.  After centrifugation, the retrotranslocated (S) 
and membrane integrated (P) populations of ubiquitinated Q394X were immunoprecipitated with 
an anti-HA antibody and visualized by SDS PAGE and phosphorimage analysis. The native 
molecular weight of Q394X is marked by an arrow.  N = 3 independent experiments, +/- SEM.    
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Figure 18. Sse1 does not affect the retrotranslocation of ubiquitinated Q394X. 
(A) In vitro ubiquitination assays were performed with cytosol and microsomes isolated from SSE1 
and sse1Δ strains.  (B) Quantification of the percentage of retrotranslocated, ubiquitinated Q394X 
is present.  After centrifugation, the retrotranslocated (S) and membrane integrated (P) populations 
of ubiquitinated Q394X were immunoprecipitated with an anti-HA antibody and visualized by 
SDS PAGE and phosphorimage analysis. The native molecular weight of Q394X is marked by an 
arrow.  N = 6 independent experiments, +/- SEM.     
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Figure 19. Hsp104 acts on ubiquitinated Q394X in the ER membrane to increase 
retrotranslocation efficiency 
(A) The membrane bound (P) fraction in a ubiquitination/retrotranslocation assay was collected 
and washed in 6 M urea to differentiate between membrane-integrated (P) and retrotranslocated, 
membrane-associated Q394X (US). Quantification of the percentage of retrotranslocated, 
ubiquitinated Q394X is present.  After centrifugation, the retrotranslocated (S), urea solubilized 
(US), and membrane integrated (P) populations of ubiquitinated Q394X were 
immunoprecipitated with an anti-HA antibody and visualized by SDS PAGE and phosphorimage 
analysis. N = 3 independent experiments, +/- SEM. The native molecular weight (arrow) and 
* 
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high molecular weight species (asterisk) of Q394X are marked. N = 4. (B) ER-enriched 
microsomes were washed with 6 M urea and collected by centrifugation. As controls, samples 
were either diluted in buffer or incubated with the strong ionic detergent, SDS.  The solubilized 
fractions (S) and the re-suspended pelleted fractions (P) were TCA precipitated and resolved by 
SDS-PAGE.  Blots were incubated with antibodies against the HA tag in Q394X, the ER-
localized integral membrane protein, Sec61, and the cytosolic proteins, Cdc48 and Hsp104.  
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Figure 20.  Degradation of Q394X in a cdc48 mutant is not rescued by over-expressing 
Hsp104. 
Mutant cdc48-3 yeast expressing Q394X and either a high copy number plasmid containing 
HSP104 (OE104) or an empty expression vector (EV) were pre-treated at 39C for 2.5 hrs and 
remained at 39C for the duration of the cycloheximide chase.  Lysates were blotted for Q394X 
levels (αHA), a loading control (αG6PDH), and Hsp104 levels (αHsp104). N = 6-7 independent 
experiments, +/- SEM.     
   
the predicted amphipathic helix could instead lead to substrate recognition by ERAD targeting 
factors.  Once an ERAD substrate is selected for degradation, various components of the cellular 
machinery are required to process the substrate for degradation (Chapter 1).  The cell possesses a 
 81 
network of factors that are important for the ubiquitination and subsequent degradation of an 
ERAD substrate, including molecular chaperones.  Previous studies utilizing Ste6* (Q1249X) have 
determined many of the factors required for its degradation by ERAD (125, 296).  Two factors that 
are important for Q1249X degradation are the cytoplasmic Hsp40, Ydj1, and Hsp70, Ssa1.  Similar 
to Q1249X, I demonstrated a requirement for both Ydj1 and Ssa1 in the degradation of the Q1249X 
analogous, less soluble Chimera A mutant, Q394X.  In addition to Ydj1 and Ssa1, I identified two 
novel cytosolic factors that are required for Q394X degradation: 1) the yeast Hsp70 Nucleotide 
Exchange Factor (NEF), Sse1, and 2) the yeast cytosolic disaggregase, Hsp104.  This is the first 
example of Hsp104 being strongly linked to the degradation of an ERAD substrate.  While Hsp104, 
Sse1, Ssa1, and Ydj1 are required for efficient Q394X degradation, I did not see a universal 
requirement of cytosolic chaperones for Q394X degradation.  Some of these dispensable factors 
are known to interact with, and often act in similar folding pathways, as the chaperones discussed 
above (48, 310, 311).  Therefore, I believe that the requirement for Hsp104, Sse1, Ssa1, and Ydj1 
in Q394X degradation is specific and not due to a general stress response in the cell.   
While Ssa1 and Ydj1 are required for the degradation of both Q1249X (Ste6*) and Q394X, 
the degradation of these substrates exhibited different Hsp104 dependencies.  I observed a strong 
stabilization of Q394X degradation in the absence of Hsp104 function while Q1249X degradation 
was unaffected.  There are two potential explanations for this result: 1) the two NBDs present in 
Q1249X are able to interact, which reduces the insolubility and aggregation propensity of the 
truncated NBD of Q1249X or 2) the NBDs in Q1249X may interact with the transmembrane 
domains (TMDs) not present in Q394X, which helps to mask the insolubility and aggregation 
propensity of the truncated NBD.  Evidence from solved structures and ATP hydrolysis assays of 
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Figure 21. Model for role of Hsp104 in the ERAD of Q394X. 
In yeast, there exists two populations of Q394X in the ER-membrane: 1) aggregated and 2) non-
aggregated in the ER-membrane.  Cellular stress, in this case heat shock, can lead to an increase 
in the aggregated population of Q394X.  This aggregated population of Q394X is ubiquitinated by 
cellular components and (A) disaggregated in the ER membrane by Hsp104.  This disaggregated 
population is then able to be retrotranslocated by Cdc48 into the cytosol where it is degraded by 
the 26S proteasome.  (B) However, loss of Hsp104 leads the increased presence of aggregates.  
These aggregates are still ubiquitinated but can no longer be retrotranslocated by Cdc48, leading 
to the decreased degradation of Q394X.     
 
other ABC transporters strongly suggest that the NBDs of ABC transporters dimerize for efficient 
function (314, 315).  Similarly, there is evidence that suggests the interactions between NBDs and 
TMDs are required for efficient protein folding and transport (316-318).  While interactions 
between the NBDs and NBDs/TMDs has not been thoroughly studied in Ste6, it has been 
demonstrated that the ectopic expression of  the two halves of Ste6 results in rescue of mating in 
a ste6Δ mutant (319).  This result suggests that the two halves of Ste6 are able to associate in some 
way that allows for proper channel function.   
There are several potential roles for how these cytosolic chaperones could facilitate the 
degradation of Q394X.  Both Ssa1 and Ydj1 have been demonstrated to be required for the efficient 
ubiquitination of multiple ERAD substrates (19, 141).  Similar to the Ssa1 role for ubiquitination 
of other ERAD substrates, I demonstrated that Ssa1 is required for efficient Q394X ubiquitination.  
Unlike Ssa1, it does not appear that Hsp104 is required for Q394X ubiquitination.  Therefore, I 
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hypothesized that Hsp104 is playing a role in Q394X degradation downstream of substrate 
ubiquitination.     
One potential post-ubiquitination step in ERAD that Hsp104 facilitate is substrate 
retrotranslocation.  Currently, it is understood that after substrate ubiquitination, substrates are 
retrotranslocated from the ER into the cytosol by the AAA+ ATPase, p97/Cdc48 (57).  To this 
end, it appears that Hsp104 localizes to puncta under heat shock only when we express Q394X.  
One caveat to that is a lack of co-localization of these puncta to the ER, which will need to be done 
in the future.  Furthermore, I observed a shift of Q394X to a denser fraction in a sucrose gradient 
in hsp104Δ cells, suggesting that Q394X is aggregating in the absence of Hsp104.  The 
ubiquitination of this population of Q394X suggests it has been selected for ERAD.  The more 
dense population of Q394X that appears in the absence of Hsp104 co-localizes to a fraction where 
the ER-resident protein, Sec61, is present.  Therefore, this result can be interpreted in one of three 
ways: 1) Hsp104 is important for the efficient retrotranslocation of Q394X from the ER to the 
cytosol, 2) Hsp104 acts to maintain Q394X solubility or disaggregates Q394X post-
retrotranslocation, or 3) Hsp104 acts to actively retrotranslocate Q394X into the cytosol.  In 
mammalian cells, the Bag6 complex binds retrotranslocated substrates in the cytosol to maintain 
their solubility prior to degradation by the 26S proteasome (112).  However, in yeast, there is no 
Bag6 homolog, meaning that other cytosolic proteins may be performing this function in yeast.  
Recently, Cdc48 was identified to maintain the solubility of a retrotranslocated ERAD substrate 
prior to degradation (320).  Based on our results, it is possible that Hsp104 is performing a similar 
function as Cdc48 for the Q394X protein.    
By further addressing the specific role of Hsp104, I was able to show a lower amount of 
retrotranslocated, ubiquitinated Q394X in the in vitro ubiquitination assays when Hsp104 function 
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is lost.  This effect appears to be due to a decreased efficiency of retrotranslocation and is not due 
to the aggregation of ubiquitinated Q394X after it has been retrotranslocated into the cytosol, as 
urea is not able to rescue the solubility of ubiquitinated material.  Therefore, what is pelleted is 
still integrated in the ER membrane.  Furthermore, the decreased efficiency of Q394X 
retrotranslocation is also not due to Hsp104 actively retrotranslocating Q394X, as over-expression 
of Hsp104 in a cdc48 mutant was unable to rescue Q394X degradation.  Additionally, 
overexpression of Hsp104 was unable to rescue the growth phenotype of the cdc48 mutant at 39°C 
(data not shown).  Together, these results suggest that while they are both AAA+ ATPases, Hsp104 
and Cdc48 function differently in cells and Hsp104 is unable to compensate for the loss of Cdc48 
function.  Based on these results, I hypothesize that Hsp104 is responsible for disaggregating 
Q394X in the ER membrane, which allows for more efficient retrotranslocation of ubiquitinated 
Q394X by Cdc48.   
Due to the nature of cytosolic aggregates, such as aggresomes, and the known function of 
Hsp104, it is reasonable to hypothesize that Hsp104 localizes to Q394X aggregates in the ER 
membrane.  Disease-linked aggresomes contain a variety of heat shock proteins, such as Hsp70, 
Hsp40, Hsp90, and others (321).  Because Q394X appears to remain in the ER membrane prior to 
Hsp104 activity, it is also possible that ER-resident proteins associate with these aggregates.  
Q1249X and CFTR were previously shown to reside in sub-compartments of the ER, called ER 
associated compartments (ERACs), where they remain prior to degradation by ERAD (322).  
These compartments contain wild type ER-resident proteins as well, such as Kar2, Ste14, and 
Sec63.  However, normal trafficking of secretory proteins was not disturbed by the presence of 
ERACs.   
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In terms of the predicted model for Hsp104 activity in the degradation of ubiquitinated 
Q394X, I hypothesize that Hsp104 recruitment to the aggregated Q394X is not driven by 
interaction with ubiquitin.  Instead, I hypothesize that Hsp104 recognizes the aggregated 
population directly and acts to hand off the disaggregated, ubiquitinated Q394X to Cdc48 for 
retrotranslocation.  This could explain the presence of a high molecular weight species of 
ubiquitinated Q394X that is present in the hsp104Δ reactions and not the HSP104 reactions.  
Moreover, this hypothesis fits with current results from our lab, showing a negative correlation 
between the hydrophobicity of a membrane protein and the ability of Cdc48 to retrotranslocate a 
membrane substrate (Guerriero et al., manuscript submitted for peer review). Also, Li and 
colleagues (323) recently discovered a role for Hsp104 in the disaggregation of proteins that were 
bound to the mitochondrial membrane after a heat shock.  They determined that Hsp104 function 
was important to transport proteins into the mitochondria prior to degradation.  Because Q394X 
contains a cytoplasmic degron, it is possible that Hsp104 acts similarly at the ER membrane as it 
does at the mitochondrial membrane, except to allow for export into the cytosol where substrates 
are degraded by the proteasome.       
   I identified only a small decrease in Q394X ubiquitination when Sse1 function was lost.  
However, unlike Hsp104, Sse1 does not appear to play a role in Q394X retrotranslocation.  Work 
from Bukau and colleagues (324) has shown that partial disaggregation of luciferase by the 
Ssa1/Ydj1 complex occurs upon the addition of Sse1, but addition of Hsp104 and Sse1 is required 
for fast, optimal disaggregation.  These authors also identified that the NEF activity of Sse1, and 
not its ATPase chaperone-like activity, is required for protein disaggregation.  The specific activity 
of Sse1 required for Q394X degradation will be defined in the future. 
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In summary, by using a series of truncation mutants in a single protein, I have demonstrated 
that substrate selection for ERAD is positively correlated with substrate solubility.  Furthermore, 
I have identified several cytosolic chaperones that are important for the degradation of a relatively 
insoluble protein.  One of these chaperones, Hsp104, has never before been shown to be important 
for ERAD.  I also provide data that Hsp104 acts to disaggregate a relatively insoluble protein, 
which is important for the efficient retrotranslocation of the substrate by Cdc48.  In the future, it 
will be interesting to identify how mammalian cells deal with this insoluble protein to maintain 
homeostasis in the cell. 
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3.0  CONCLUSIONS 
In this thesis, I set out to address the mechanism by which cells recognize an ERAD substrate.  To 
do this, I utilized a novel truncation series in a domain, NBD2 of Ste6, that has previously been 
used to characterize the degradation of a 12 transmembrane ERAD substrate, Ste6* (125, 284, 
296), as well as the cytoplasmic quality control (cytoQC) system required to degrade the 
cytoplasmic form of this domain, called NBD2* (285).  Prior to my work, Drs. Meredith Metzger 
and Susan Michaelis from Johns Hopkins University School of Medicine created a series of 
truncations in the Ste6 NBD2 that reside both N-terminal and C-terminal to the site of truncation 
in Ste6* (Q1249X).  Utilizing this Ste6 truncation series, they identified a subset of these 
truncations that were degraded as efficiently as Ste6*.  However, not all of the truncations were 
similarly degraded.  Two truncations were identified that had similar metabolic stabilities to that 
of the wildtype Ste6: one truncation was more N-terminal (L1240X) and one truncation was more 
C-terminal (R1268X) to the Q1249X truncation.  Therefore, I aimed to address why the difference 
of only a few amino acids can cause a protein to exhibit drastically different stabilities.  To 
determine the effects these truncations have on the NBD2 domain, I utilized a novel protein, called 
Chimera A.  Chimera A consists of two transmembrane domains annealed to the NBD2 of Ste6.  
Utilizing this protein should reduce intramolecular interactions that can alter the properties that are 
important for substrate recognition and degradation by ERAD.  Importantly, we were able to show 
that the analogous truncations in Chimera A appear to have similar trends in their metabolic 
stabilities as their Ste6 counter parts.   
The observation that truncating the C-terminus of Ste6 and Chimera A is not sufficient to 
lead to a decrease in metabolic stability is different than what was observed for another ERAD 
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substrate (312).  Therefore, we hypothesized that a difference in the metabolic stabilities of the C-
terminal truncations is likely caused by a change in the properties of the substrates.   To date, there 
are several models to explain which substrate properties lead to ERAD substrate selection.  These 
models suggest different alterations to the protein: 1) the exposure of an amphipathic helix (270-
272), 2) increased substrate hydrophobicity (92, 273), and 3) loss of essential post-translational 
modifications (274, 275).     
I also set out to characterize which cellular factors are required for the degradation of a 
retrotranslocated, membrane spanning ERAD substrate.  Utilizing the Q1249X (Ste6*) analogous 
truncation in Chimera A, called Q394X, I selected a series of cytoplasmic factors to begin 
investigating their potential roles in Q394X degradation.  I first sought to show a similar 
dependence on cytoplasmic chaperones known to be important for Q1249X degradation.  Once I 
was able to identify commonly required factors, I next intended to identify novel cytoplasmic 
chaperones required for Q394X degradation.  Interestingly, I identified one novel factor, the 
cytoplasmic disaggregase, Hsp104.  Because Hsp104 has never before been linked to ERAD, I set 
out to better characterize its role in the degradation of Q394X.        
Previous investigations into the cellular components required for the ERAD of Ste6* have 
identified multiple factors (125, 296).  Of these, two were of particular interest to me: 1) the 
cytoplasmic Hsp40 (Ydj1) and 2) the cytoplasmic Hsp70 (Ssa1).  One important role for these 
molecular chaperones in Ste6* degradation is in substrate ubiquitination (19).  The importance of 
cytoplasmic factors for the ubiquitination and degradation of ERAD substrates has long been 
established (See Chapter 1).  However, there has not been a definitive requirement in ERAD for 
the cytoplasmic disaggregase, Hsp104.  Hsp104 functions in a complex to disaggregate proteins 
with Ssa1, Ydj1, the yeast small heat shock proteins, Hsp26 and Hsp42, and the yeast nucleotide 
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exchange factor, Sse1 (48, 303, 305, 309).  Based on the known cellular role for Hsp104, there 
could be several potential functions for Hsp104 in ERAD: 1) disaggregating the substrate in the 
membrane, 2) disaggregating the substrate once it is retrotranslocated into the cytoplasm, or 3) 
assisting Cdc48 in the retrotranslocation of Q394X. 
Cdc48 is the cytoplasmic AAA+ ATPase that is responsible for retrotranslocating 
substrates from the ER to the cytoplasm, where they are subsequently degraded by the proteasome 
(57, 116).  However, Cdc48 has recently been shown to play another role in ERAD.  Specifically, 
Cdc48 is responsible for maintaining the solubility of a retrotranslocated ERAD substrate, serving 
as a holdase in the cytoplasm prior to degradation (320).  Interestingly, Ste6* was previously 
shown to be completely retrotranslocated from the ER prior to degradation, likely making it a 
candidate to require a cytoplasmic holdase (19).  To date, Cdc48 is the first holdase for 
retrotranslocated ERAD substrates identified in yeast.  However, in mammalian cells, other 
complexes have been identified to serve as a holdase for retrotranslocated ERAD substrates.  Most 
notable is the Bag6 complex, which consists of Bag6 and the components of the tail-anchored 
protein insertion complex, UBL4A, TRC35, and SGTA (283).  In yeast, there is no homolog for 
the key component of this complex, Bag6. Therefore, it is possible that other factors, such as 
Hsp104, may also serve as holdases in the yeast cytoplasm.  
In this thesis I report new discoveries about the process of ERAD and novel factors that 
play a role in this pathway.  These findings are as follows: 
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3.1 TRUNCATIONS WITHIN THE NBD2 IN CHIMERA A LEAD TO HIGHLY 
VARIABLE EFFECTS ON PROTEIN METABOLIC STABILITY   
As mentioned above, I have shown that a series of truncations in an ER-tethered form of the NBD2 
behave similarly to what was observed by Drs. Meredith Metzger and Susan Michaelis for the 
analogous truncations in Ste6.  Specifically, I determined that the Chimera A truncations separate 
into two groups.  One group has a significantly reduced metabolic stability when compared 
Chimera A.  The second group has a similar metabolic stability to that of Chimera A.  Importantly, 
these differences in metabolic stability do not simply correlate with how far into the domain I 
truncate, as the mutant with the largest truncation I tested (L385X) was equally as stable as 
Chimera A.  Meanwhile, the mutant with a truncation two amino acids more C-terminal (M387X) 
was significantly less stable.  Use of a homology model suggests that the more stable truncations 
appear to occur at the beginning or end of a β-sheet in the NBD2 structure while those that are less 
stable appear to disrupt the β-sheet.  Therefore, I hypothesize that disrupting this β-sheet leads to 
a significant change in the properties of the substrates, leading to enhanced degradation.   I also 
demonstrated that the Chimera A truncation series is degraded via ERAD, as several of the 
truncations localize to the ER, require Doa10 and Hrd1 for degradation, and are significantly 
stabilized when the proteasome is inhibited.  
To address the predicted structural changes to the NBD of Ste6/Chimera A when truncated 
at the different sites, I used Phyre2 to predict the resulting structures for several of the truncations.  
Results from these predictions did not suggest any drastic alterations to the overall predicted NBD 
structure when compared amongst the modelled truncations. For example, when I compared the 
models for the L385X vs the M387X truncations, it appears that the major change is to the 
predicted secondary structure of the C-terminus.  In the case of L385X, Phyre2 suggests that the 
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C-terminus ends in an α-helix that bundles with other predicted α-helices in the protein.  For 
M387X, Phyre2 instead predicts the C-terminus to partially interact with a core β-sheet preceded 
by a long unstructured region.  It is possible that this change in predicted secondary structure helps 
components of ERAD to recognize M387X as being more misfolded.  However, these are only 
homology models and it is possible that disrupting the C-terminus through truncation has greater 
effects on the NBD structure, potentially as the proteins are being synthesized and attempt to fold 
co-translationally.  Therefore, I am unable to definitively state the exact effect these truncations 
have on the NBD structure that leads to selection for ERAD.  It is possible that there is a level of 
protein unfolding that represents a threshold: Crossing over this threshold could then result in 
select misfolded substrates being more efficiently selected for ERAD than others.   
3.2 THE METABOLIC STABILITY OF THE CHIMERA A TRUNCATION SERIES 
POSITIVELY CORRELATES WITH SUBSTRATE SOLUBILITY 
To determine which substrate properties may be altered by these truncations, leading to increased 
turnover, I investigated substrate solubility.  Specifically, I identified that the less stable 
truncations also exhibited reduced detergent solubility.  I demonstrated that this reduced detergent 
solubility is not due to differences in substrate extraction from the membrane, as the solubility of 
the less stable construct, Q394X, was rescued to similar levels as those of Chimera A with the 
addition of urea.  I hypothesize that the destabilizing truncations lead to decreased solubility, which 
increases their recognition and degradation by ERAD.  While this hypothesis favors the model 
where hydrophobicity is responsible for driving substrate selection for ERAD, it is interesting to 
apply these findings to a model that instead suggests the exposure of an amphipathic helix leads 
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to substrate recognition for ERAD.  In one of the findings supporting the second hypothesis, an 
amphipathic helix that becomes exposed in an ERAD substrate is a very hydrophobic (271).  It is 
possible then that it is not necessarily the exposure of the secondary structure, but instead, the 
exposure of the hydrophobic regions within the unstable amphipathic helix that lead to increased 
ERAD.  Importantly, investigators never studied the solubility of the unstable construct that 
contained an exposed amphipathic helix.  Therefore, it could be that insolubility is also responsible 
for increased degradation of their substrate by ERAD. 
3.3 HSP104 IS IMPORTANT FOR THE DISAGGREGATION OF Q394X IN THE 
MEMBRANE, WHICH ALLOWS FOR THE EFFICIENT RETROTRANSLOCATION 
AND DEGRADATION OF THE ERAD SUBSTRATE 
I demonstrated a requirement for Hsp104 in Q394X degradation, as the loss of Hsp104 activity 
leads to increased Q394X metabolic stability.  I further determined that Hsp104 acts downstream 
of substrate ubiquitination, unlike two other factors I identified as being important for Q394X 
degradation, Ssa1 and Ydj1.  To define the role played by Hsp104 downstream of substrate 
ubiquitination, I utilized a density floatation assay to show that Q394X shifts to a denser fraction 
in the absence of Hsp104 function.  This shift in Q394X density is interesting, as Hsp104 was 
shown to localize to the puncta under conditions where Hsp104 is required for Q394X degradation.  
This more dense population of Q394X was still ubiquitinated and co-localized with the ER, which 
was identified by monitoring the density at which Sec61 resides.   
Based on these results, it is possible that Hsp104 helps retrotranslocate Q394X.  I next 
demonstrated that in the absence of Hsp104 activity, Q394X is less efficiently retrotranslocated, 
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as the altered ratio of ubiquitinated Q394X in the soluble fraction is not caused by aggregation of 
Q394X after release from the membrane.  However, Hsp104 does not appear to actively 
retrotranslocate Q394X, as over-expression of Hsp104 was unable to rescue a cdc48 mutant.  
Therefore, I hypothesize that Hsp104 acts to disaggregate Q394X at the membrane, which allows 
for its increased efficiency of retrotranslocation by Cdc48. 
3.4 THE YEAST NUCLEOTIDE EXCHANGE FACTOR, SSE1, ALSO ACTS 
DOWNSTREAM OF Q394X RETROTRANSLOCATION  
Along with Hsp104, I found that Sse1 is important for the degradation of Q394X.  However, unlike 
Hsp104, I demonstrated that Sse1 is not required for Q394X retrotranslocation.  Since loss of Sse1 
activity only mildly affects Q394X ubiquitination, I hypothesize that Sse1 instead acts downstream 
of substrate retrotranslocation.  Previously, Sse1 was demonstrated to maximize 
Hsp40/Hsp70/Hsp104 disaggregation activity (324).  Also, in vitro, Hsp110, the mammalian 
homolog of Sse1, acts with Hsp70 to disaggregate proteins (302).  Therefore, further investigation 
into the role of Sse1 in the degradation of Q394X is warranted.   
3.5 IMPLICATIONS OF MY WORK ON PROTEIN FOLDING AND DISEASE 
Protein aggregation has long been identified as a hallmark for multiple human neurodegenerative 
diseases, including Parkinson’s Disease, Alzheimer’s Disease, and Huntingtin’s Disease.  For 
some of these disease, problematic proteins improperly fold, leading to increased intermolecular 
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interactions, such as amyloid formations (51).  The formation of these amyloid structures results 
from the packing of β-sheets into highly structured, low free energy conformations (325).  At the 
protein folding level, β-sheets require partner amino acids that reside in more distant regions of 
the protein. These distant interactions are believed to lead to an increase in the amount of time 
required to complete folding compared to α-helices (326).  This propensity for β-sheet-rich 
proteins to form improper intermolecular interactions, along with the increased time required for 
folding, leads to my hypothesis that disrupting β-sheets in select chimeras leads to decreased 
protein stabilization. 
While the exact population of aggregated proteins responsible for neurotoxicity in diseases 
has yet to be definitively identified, it is understood that aggregated proteins can be responsible 
for cell toxicity.  These aggregates can sequester other proteins, and can be transmitted between 
cells (327-329).  As a result, there is a benefit that could be gained by identifying mechanisms for 
clearing these problematic aggregates.  While there is no current homologue of Hsp104 in 
mammalian cells, work from Dr. James Shorter’s lab at the University of Pennsylvania has 
demonstrated the ability of purified Hsp104 to break-up mammalian aggregated proteins that are 
linked to disease (330). In fact, upon introducing a single point mutation into the regulatory M-
domain of Hsp104 (A503V), Hsp104 was more efficiently able to resolve aggregates containing 
the neurodegenerative-linked proteins, FUSE, TDP-43, and α-synuclein.  This finding suggests a 
potential therapeutic role for Hsp104 in multiple neurodegenerative diseases.  To this end, two 
potential functional orthologues for Hsp104, called RuvbL1 and RuvbL2, have recently been 
identified (331).  Further characterization of these proteins could allow for a native mammalian 
protein to be targeted to treat neurodegenerative diseases.                
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3.6 FUTURE WORK  
Future work on this project can be split into two groups: 1) Short term investigations and 2) Long 
term investigations.  I will now discuss what would be done next if I had more time to work on 
this project or what I would suggest for the person who takes over my project: 
3.6.1 Short Term 
I would first address two important points regarding the data presented here in my thesis.  First, I 
would better attempt to link a dependence on Hsp104 for the degradation of the less soluble and 
less stable Chimera A truncations.  While I have tried doing metabolic stability studies at multiple 
elevated temperatures in the hsp104Δ strains expressing Chimera A, Q394X, L385X, and I389X, 
which consist of both stable and unstable proteins, the substrates consistently seem to acquire 
Hsp104 dependence.  This is likely because they are chimeric proteins, most of which contain 
altered domains.  Because we only see an Hsp104 dependence for Q394X degradation at higher 
temperatures, this presents a problem.  Hsp104 is expressed at low levels at 25°C (332).  Instead, 
Hsp104 was shown to be upregulated after heat shock at 39°C.  Therefore, minimal Hsp104 levels 
in wildtype cells could be why we see no effect on Q394X degradation in the hsp104Δ strain at 
26°C.  To address this, I would over-express Hsp104 in the wild type (BY4742) strains expressing 
the four substrates listed above.  I would then determine if any of their metabolic stabilities are 
further decreased when Hsp104 is over-expressed at 25°C.  I hypothesize that the metabolic 
stabilities of Q394X and I389X will be even further decreased when Hsp104 is over-expressed 
compared to Chimera A and L385X.   Finally, I would demonstrate that Hsp104-GFP co-localizes 
to the ER through the expression of Sec63-mCherry.  Cells containing an empty vector or Q394X 
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along with DMSO or MG132 to inhibit the proteasome would be temperature shifted.  I will 
measure the number of cells with Hsp104-GFP puncta that co-localize to Sec63-mCherry.  I 
hypothesize that only when we express Q394X will we see co-localization of Hsp104-GFP and 
Sec63-mCherry, demonstrating that Hsp104 localizes to the ER membrane under conditions where 
Hsp104 is required for the degradation of Q394X.       
Next, I would continue to investigate the role of Sse1 in the degradation of Q394X.  To 
start, I would utilize the floatation assay with the SSE1 and sse1Δ strains the same way I did for 
the HSP104 and hsp104Δ strains.  Because I hypothesize that Sse1 acts after Q394X 
retrotranslocation, I anticipate that Q394X will shift to even denser fractions, most likely localizing 
to the cytoplasm.  Next, I would utilize a series of Sse1 constructs that contain point mutations in 
the ATPase domains of Sse1 (333).  These constructs were shown to rescue the sse1Δ growth 
defect under stress conditions.  Therefore, we may be able to determine the ability of Sse1 to act 
as a holdase for retrotranslocated Q394X.   
Another important next step would be to identify other substrates that exhibit a positive 
correlation between stability and solubility.  I have begun to work with three synthetic constructs 
(αS824, β4, and β23) that were previously shown to aggregate and cause cell death at different 
rates when expressed in the cytoplasm (334).  The next step would be to successfully clone these 
proteins and anneal them to tm1-2 of Chimera A to anchor them in the ER membrane.  I would 
characterize their localization and dependence on ERAD for degradation, followed by correlating 
their degradation rate with their solubility.  I would further determine chaperone dependence for 
the degradation of these transmembrane proteins, specifically focusing on correlating them with 
those identified to be important for the degradation of Q394X.  This would allow me to begin to 
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potentially identify a specific group of chaperones that are required for the clearance of insoluble 
transmembrane proteins within cells.     
In our lab, we have also begun to investigate the correlation between stability and solubility 
for two Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) mutants that have been 
linked to Cystic Fibrosis (CF).  These mutants consist of a point mutation in the second NBD of 
CFTR (N1303K) and a truncation in the second NBD of CFTR (W1282X).  We currently have a 
set of model substrates, consisting of tm1-2 of Chimera A annealed to these mutant NBDs of 
CFTR, along with a construct consisting of tm1-2 annealed to the full-length NBD2 of CFTR.  
Preliminary stability assays have determined that the W1282X mutation significantly decreases 
substrate expression and substrate stability compared to the wild type CFTR NBD2 chimera.  The 
N1303K mutation on the other hand appears to make the CFTR chimera more stable.  I would 
further characterize the localization of these proteins, their dependence on ERAD and molecular 
chaperones for degradation, and determine their solubilities via the detergent solubility assay.  
These chimeras are of particular interest as they would help to characterize the effects these 
mutations have on the properties of CFTR and contribute important information to the field of 
CFTR research.     
3.6.2 Long Term 
The major project to be continued in the long term would be shifting this work into mammalian 
cells.  I would first clone the Chimera A truncation series into a mammalian expression vector and 
transform them into HEK293T cells, which were previously used to identify cytoplasmic factors 
that associate with transmembrane ERAD substrates (112).  I would then determine if stability and 
solubility once again positively correlate, through cycloheximide chases and detergent solubility 
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assays.  If stability and solubility are positively correlated, I would utilize Q394X for two separate 
approaches.  First, I would specifically investigate the role of Bag6 and the Hsp104 functional 
orthologues, RuvbL1 and RuvbL2 (331), for a role in Q394X stability in mammalian cells.  
Second, I would perform pull downs with cells expressing Q394X vs Chimera A and submit 
samples for mass spec analyses to determine what factors associate with Q394X.  With hits from 
the mass spec results, I would determine potential mechanisms for their role in Q394X degradation 
in mammalian cells.  It would be interesting to compare what I learn through both the targeted 
(Bag6, RuvbL1, and Ruvbl2) and non-biased (mass spec) research directions to that which I 
learned in yeast that is reported in this thesis.  This research direction presents a potential to identify 
new factors in mammalian cells that are important for the processing of transmembrane ERAD 
substrates.  
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APPENDIX A 
 YEAST STRAINS, PLASMIDS, AND OLIGONUCLEOTIDES USED IN THIS STUDY 
 
Table 2. Yeast Strains Used in This Study  
Strain Relevant Genotype Reference/Source 
SM2721 MATa trp1 leu2 ura3 his4 can1 ste6-∆5(8-1290) (288) 
BY4742 MATα his3Δ1, leu2Δ0, lys2Δ0, ura3Δ0 Invitrogen 
pdr5Δ MATα his3Δ1, leu2Δ0, lys2Δ0, ura3Δ0  pdr5Δ::KAN Open Bio Systems 
sgt2Δ MATα his3Δ1, leu2Δ0, lys2Δ0, ura3Δ0 sgt2::KAN Open Bio Systems 
HSP104 
MATa ura3-52 lys2-801 ade2-101 trp1-Δ63 his3-Δ200 leu2-
Δ1 
(335) 
hsp104Δ 
MATa ura3-52 lys2-801 ade2-101 trp1-Δ63 his3-Δ200 leu2-
Δ1 hsp104::LEU2 
(305) 
SSA1 
MATα his3-11,15 leu2-3,112 ura3-52 trp1-Δ1 lys2 SSA1 
ssa2- 1::LEU2 ssa3-1::TRP1 ssa4-1::LYS2 
(336) 
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ssa1-45 
MATα his3-11,15 leu2-3,112 ura3-52 trp1-Δ1 lys2 ssa1-45 
ssa2-1::LEU2 ssa3-1::TRP1 ssa4-1::LYS2 
(336) 
W303-1B 
MATα ade2-1 his3-11,15 leu2-3,112 ura3-1 trp1-1 can1-
100  
(337) 
ydj1-151 
MATα ade2-1 his3-11,15 leu2-3,112 ura3-1 trp1-1 can1-
100 ydj1-2::HIS3 ydj1-151::LEU2 
(337) 
sse1Δ 
MATα ade2-1 his3-11,15 leu2-3,112 ura3-1 trp1-1 can1-
100 sse1::KAN 
(338) 
CCT1 
MATα leu2-3,112 ura3-52 trp1-7 tcp::LEU2 (YCpMS38; 
TCP1::TRP1) 
(339) 
cct1-2 
MATα leu2-3,112 ura3-52 trp1-7 tcp::LEU2 (YCpMS38; 
tcp1-2::TRP1) 
(339) 
HSP26 HSP42 
MATa ura3-52 leu2-3,112 his3-Δ200 trp1-Δ901 ade2-101 
suc2-Δ9 GAL 
(340) 
hsp26Δ 
hsp42Δ 
MATa ura3-52 leu2-3,112 his3-Δ200 trp1-Δ901 ade2-101 
suc2-Δ9 GAL hsp26::HIS3 hsp42::LEU2 
(340) 
rad23Δ dsk2Δ 
MATa, his3∆1, leu2∆0, ura3∆0, rad23∆::KanMX, 
dsk2∆::KanMX 
(125) 
HSP104-GFP 
MATa, pdr5Δ::kanMX4 can1Δ::STE2pr-Sp_his5, lyp1Δ, 
ura3Δ0, met15Δ0, HSP104-GFP-LEU2 
Nystrom lab 
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Table 3. Yeast Plasmids and primers used in this study 
 Name Relevant Genotype/Sequence  Reference 
 Plasmid 
pSM694 2µ LEU2 STE6::HA (288) 
pSM1175 2µ LEU2 ste6-L1240X::HA This study 
pSM1176 2µ LEU2 ste6-M1242X::HA This study 
pSM1177 2µ LEU2 ste6-I1244X::HA This study 
pSM1178 2µ LEU2 ste6-H1246X::HA This study 
pSM1179 2µ LEU2 ste6-M1251X::HA This study 
pSM1180 2µ LEU2 ste6-S1256X::HA This study 
pSM1264 2µ LEU2 ste6-R1268X::HA This study 
pSM1400  2µ LEU2 ste6-K1261X::HA This study 
pSM2319 2µ LEU2 ste6-Q1249X::HA This study 
pCG19 2µ URA3 Chimera A::HA This study 
pCG12 2µ URA3 chimera A-Q394X::HA This study 
pKN31 2µ HIS3 Pcup1-mycUb-Tcyc1 (19) 
pMP01 2µ URA3 chimera A-L385X::HA This study 
pMP02 2µ URA3 chimera A-M387X::HA This study 
pMP03 2µ URA3 chimera A-I389X::HA This study 
pMP04 2µ URA3 chimera A-H391X::HA This study 
pMP05 2µ URA3 chimera A-M396X::HA This study 
pMP06 2µ URA3 chimera A-S401X::HA This study 
pMP07 2µ URA3 chimera A-K406X::HA This study 
pMP08 2µ URA3 chimera A-R413X::HA This study 
pMP09 2µ  LEU2 HSP104 This study 
pMP10 2µ LEU2 P-GPD HSP104 This study 
Primers 
oMP01 5’-
GCGCCCGGGATGAACTTTTTAAGTTTTAAGAC-3’ 
This study 
oMP02 5’-
CGCCCGCGGTTATAGAGCAGGTGGACCTTTTTTG
ACC-3’ 
This study 
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oMP03 5’-
CGCCCGCGGTTATGTTAGTAGAGCAGGTGGACC-
3’ 
This study 
oMP04 5’-
CGCCCGCGGTTAAACCATTGTTAGTAGAGCAGG
TGGACC-3’ 
This study 
oMP05 5’-
CGCCCGCGGTTACGTTATAACCATTGTTAGTAGA
GCAGG-3’ 
This study 
oMP06 5’-
CGCCCGCGGTTACATTTGTTCACTATGCGTTATA
ACC-3’ 
This study 
oMP07 5’-
CGCCCGCGGTTAGTTACAAGACCTCATCATTTGT
TCAC-3’ 
This study 
oMP08 5’-
CGCCCGCGGTTAAAGAACTGCAATCGAGTTACA
AGACC-3’ 
This study 
oMP09 5’-
CGCCCGCGGTTACTCAACCACTTTACCATCTTTA
AG-3’ 
This study 
oMP10 5’GAAGTAATTATCTACTTTTTACAACA
 
 
 
 
 
This study 
oMP11 5’CGCGGATCCATGAACGACCAAA-3’ This study 
oMP12 5’CGCCTGCAGTTAATCTAGGTCATCAT
CAATTTCC-3’  
This study 
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APPENDIX B 
INTERACTIONS BETWEEN INTERSUBUNIT TRANSMEMBRANE DOMAINS 
REGULATE THE CHAPERONE DEPENDENT DEGRADATION OF AN 
OLIGOMERIC MEMBRANE PROTEIN (341) 
B.1 INTRODUCTION 
In eukaryotic cells, approximately one-third of all proteins enter the secretory pathway at the 
Endoplasmic Reticulum (ER).  Once in the ER, proteins may fold into their native states, and if 
successful continue along the secretory pathway.   However, upon cellular stress or mutations 
within the protein sequence, these secretory pathway substrates are instead degraded by a process 
called Endoplasmic Reticulum-Associated Degradation (ERAD).  ERAD is an important area of 
research for several reasons, including the connection between substrate clearance/aggregation and 
human disease (269).   
 One such ERAD substrate that is linked to human disease is the epithelial sodium 
channel, ENaC.  ENaC is a heterotrimeric membrane protein consisting of an alpha, beta, and 
gamma subunit that are assembled in the ER and function at the plasma membrane in the kidney 
to transport sodium (342).  Altered function of the ENaC channel can lead to several diseases, 
including Liddle’s syndrome and pseudohypoaldosteronism type I (343, 344).  It was shown 
previously that ERAD of the non-glycosylated population of the alpha subunit of ENaC requires 
the function of the ER-luminal Hsp70 cochaperone, called Lhs1 in yeast and GRP170 in 
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mammalian cells (345).  However, the role of Lhs1 in the degradation of αENaC, along with the 
mechanism of recognition of αENaC by Lhs1, had not yet been identified.  To address these 
questions, I collaborated with Dr. Teresa Buck in the Brodsky lab to test the hypothesis that non-
glycosylated αENaC is recognized by Lhs1 due to decreased solubility and that Lhs1 subsequently 
plays a role in non-glycosylated αENaC retrotranslocation prior to degradation.    
B.2 MATERIALS AND METHODS 
B.2.1 Detergent Solubility Assay 
BY4742 and lhs1Δ strains constitutively expressing αENAC or the mutant αENaC containing no 
glycosylation sites, called ΔG αENAC, were grown to a final OD600 of 1.5 in 4 liters of culture.  
Cultures were shifted to 37°C for 1 hr, shaking at ~160 rpm in a water bath.  Cells were harvested 
by centrifugation for 5 min at 5000 rpm and 4°C in a Piramoon F7S-4x1000Y rotor.  Once 
harvested, ER-enriched microsomes were isolated using a previously described large scale 
technique (294).  The microsomes were incubated with Buffer 88 (20 mM HEPES–NaOH, pH 6.8, 
150 mM potassium acetate, 5 mM magnesium acetate, 250 mM sorbitol), and the indicated 
concentration of the non-ionic detergent, n-Dodecyl β-D-maltoside. Each sample contained a final 
concentration of roughly 0.5 mg/mL of protein.  For controls, one sample was resuspended in 
Buffer 88 alone to monitor for microsome integrity and to monitor aggregation, and one sample 
was treated with the ionic detergent, sodium dodecyl sulfate (SDS).  After the addition of 
microsomes, the samples were incubated at room temperature (~21.5°C) for 30 min.  The samples 
were then centrifuged for 10 min at 18,000 x g and 4°C in a Beckman Coulter Microfuge 22R 
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Centrifuge.   The supernatant was removed and dispensed into a new 1.5 mL Eppendorf tube, 
which contained 1:4 volume of 5x SDS sample buffer (0.325 M Tris pH 6.8, 10% SDS, 5% β-
mercaptoethanol, and 0.25 mg/mL Bromophenol Blue), and the pellet was resuspended in an equal 
volume of 1 x SDS sample buffer by pipetting.  All samples were incubated at 37°C for 30 min 
and centrifuged for 1 min at 15,000 rpm at room temperature in an Eppendorf centrifuge 5424 
microcentrifuge.  Proteins were separated on denaturing 10% polyacrylamide gels and transferred 
to nitrocellulose using the semi-dry Bio-Rad Trans Blot Turbo.  Blots were blocked in a TBST 
plus 5% milk solution for 30 min at room temperature on a rocker.  The blots were incubated for 
1.5 hrs at room temperature in a primary antibody solution against the HA tag found in both αENaC 
and ΔG αENaC (Roche Anti-HA-Peroxidase High Affinity (3F10), Rat, 1:5000).  The 
nitrocellulose blots were washed 3 times for 5 min in TBST at room temperature on a rocker.  
Bound antibodies were visualized after incubation in the SuperSignal Chemiluminescence 
(Thermo Scientific) reagent for 5 min at room temperature on a rocker, and imaged on a Bio-Rad 
Universal Hood II.  Nitrocellulose blots were stripped using 0.1 M glycine, pH 2.2 for 30 minutes, 
blocked in TBST plus milk as above, and then incubated in a rabbit primary antibody  against the 
ER integral membrane protein, Sec61 (1:5000), for 1.5 hrs at room temperature.  This served as a 
control for microsome solubilization and protein extraction.  Nitrocellulose blots were again 
washed 3 times for 5 min in TBST at room temperature and incubated 1.5 hrs in a donkey anti-
rabbit secondary antibody conjugated to HRP (1:5000, Cell Signaling Technology).  Nitrocellulose 
blots were washed 3 times for 5 min in TBST and bound antibodies were again visualized using 
SuperSignal Chemiluminescence.  Quantification was done using the ImageJ program.     
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B.2.2 In vitro Ubiquitination and Retrotranslocation Assay 
In vitro ubiquitination reactions were set-up to quantify the level of ubiquitination of ΔG αENAC 
in BY4742 vs lhs1Δ.  Yeast purified cytosol was harvested according to a previously published 
technique (294) from BY4742 cells lacking any expression vectors and that were treated at 39°C 
for 2 hours, but with one small modification.  Instead of breaking cells with a blender, cells were 
lysed using a cold mortar and pestle for 1 min, followed by the addition of liquid nitrogen.  A total 
of 6 rounds of grinding for 1 min each round was done to sufficiently break the cells. In vitro 
reactions consisted of ER-enriched microsomes purified from either BY4742 or lhs1Δ strains 
expressing ΔG αENAC, yeast purified cytosol, and the appropriate amount of a 10x ATP 
regenerating system (10mM ATP, 400 M creatine phosphate, 2 mg/mL creatine phosphokinase in 
Buffer 88).  A negative control was set up as well for both the BY4742 and the lhs1Δ reactions, 
utilizing apyrase (0.02 units/reaction) instead of the ATP regenerating system. Reactions contained 
final concentrations of 1 mg/mL microsomes, 1mg/mL cytosol (ΔG αENaC ubiqutination assays) 
or 5mg/mL (αENaC and ΔG αENaC retrotranslocation assays), the ATP regeneration system or 
apyrase, and Buffer 88.  These in vitro reactions were then pre-incubated at room temperature for 
10 min.  After the incubation at room temperature, 125I-ubiquitin was added to each reaction to a 
final concentration of 1.5 mg/mL.  Samples were then incubated at 37°C for 45 min.  For the 
retrotranslocation assays, samples were centrifuged at 18,000 x g for 10 min at 4°C.  Supernatants 
were removed and put in a fresh 1.5mL epindorf followed by resuspension of the pellets in an 
equal volume of Buffer 88.  For both assays, 125 µL of a 1.25% SDS stop solution (50 mM Tris–
Cl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 1.25% SDS, 1 mM PMSF, 1 μg/mL leupeptin, 0.5 μg/mL 
pepstatin A, and 10 mM N-ethylmaleimide (NEM)) was added to the reactions and incubated at 
37°C for 30 min.  A total of 400 µL of a Triton solution (50 mM Tris–Cl, pH 7.4, 150 mM NaCl, 
 108 
5 mM EDTA, 2% Triton X-100, 1 mM PMSF, 1 μg/mL leupeptin, 0.5 μg/mL pepstatin A, and 10 
mM NEM.), 30 µL of a 50/50 protein A-sepharose slurry, and 2.5 µL of anti-HA (Roche, mouse) 
antibody were added to each reaction.  The HA-tagged protein was then immunoprecipitated 
overnight at 4°C on a rotator.  After centrifugation, the beads were washed 3 times in an IP wash 
buffer (50 mM Tris–Cl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 0.2% SDS, 10 
mM NEM).  After all wash fluid was removed from the beads, 40 µL of TCA sample buffer (80 
mM Tris–Cl, pH 8.0, 8 mM EDTA, 0.25 M DTT, 3.5% SDS, 15% glycerol, 0.08% Tris-base, 
0.01% bromophenol blue) was added and the samples were agitated on a Vortex and incubated at 
37°C for 30 min.  Proteins were then resolved on duplicate denaturing 10% polyacrylamide gels.  
One gel was used to determine IP efficiency, and was processed for a Western blot as explained 
above.  The second duplicated gel was washed in ddH2O for 5 min, placed on filter paper, and 
dried using a Fisher Scientific Gel Dryer for 1.5 hrs.  Dried gels were then exposed to phosphorfilm 
for 2-3 days.  The phosphorfilm was scanned using a Typhoon FLA 7000.        
B.3 RESULTS 
B.3.1 The Lhs1-dependent non-glycosylated population of αENaC is less soluble than the 
glycosylated population of αENaC, independent of Lhs1 function 
Previous work from Buck et al. (345) first identified Lhs1 as an important factor in the ERAD of 
αENaC, but the role and mechanism of substrate recognition by Lhs1 was not addressed. To 
address why Lhs1 selectively recognizes the non-glycosylated population of αENaC, I utilized a 
detergent solubility assay to determine the relative solubility of the glycosylated and 
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unglycosylated populations of αENaC in the lhs1Δ strain.  ER-enriched microsomes containing 
αENaC were purified from lhs1Δ yeast and treated with varying levels of DDM.  As shown in the 
figure, below (part A), the glycosylated population appears to be more soluble when compared to 
the non-glycosylated population of αENaC across all DDM concentrations.  Importantly, there is 
no difference between the two populations of αENaC when we treat microsomes in the absence of 
detergent (the material remained in the pellet fraction) or when we use the ionic detergent, SDS, 
which liberated nearly all of the protein.  These results suggest that the two populations of αENaC 
are still in the membrane after microsome purification and are both able to be solubilized by a 
strong detergent.  
To address whether Lhs1 activity alters the solubility of the non-glycosylated population 
of αENaC, I purified ER-enriched microsomes from both a wildtype strain (BY4742) and an lhs1Δ 
strain expressing ΔG αENaC.  These microsomes were once again treated with DDM and their 
relative solubilities were determined by western blot.  Regardless of whether Lhs1 is present in 
cells, ΔG αENaC is equally soluble at the various DDM concentrations (part B).  In contrast, as 
above, ΔG αENaC was insoluble and remained in the pellet fraction when detergent was absent 
and was readily solubilized by SDS.   These results suggest that while the non-glycosylated 
population of αENaC is less soluble than the glycosylated population, Lhs1 has no effect on 
maintaining substrate solubility. 
B.3.2 Deletion of LHS1 leads to increased ubiquitination of non-glycosylated αENaC but 
decreased retrotranslocation of ubiquitinated αENaC 
Because Lhs1 is required for non-glycosylated αENaC degradation, we wanted to address what 
role Lhs1 plays in the ubiquitination of αENaC.  Therefore, to enhance the signal corresponding 
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to ubiquitinated protein, I used the ΔG αENaC construct.  I then used an established ubiquitination 
assay from the lab to determine what role Lhs1 plays in the ubiquitination of αENaC (294).  In this 
assay, we incubate ER-enriched microsomes containing our substrate with purified yeast cytosol 
and radioactively labeled ubiquitin.  With the addition of ATP, our substrate is ubiquitinated and 
retrotranslocated, which we can monitor through the radioactivity.  Surprisingly, unlike other 
Hsp70 cochaperones, such as the cytoplasmic Hsp40, Ydj1 (19, 141), Lhs1 deletion did not 
decrease ΔG αENaC ubiquitination (part C).  Instead, there appears to be a 3-4 fold increase in ΔG 
αENaC ubiquitination when using membranes prepared from the lhs1Δ strain compared to 
membranes from the wildtype (BY4742) strain.   
Since Lhs1 appears to play a role in the ubiquitination of non-glycosylated αENaC, I also 
investigated the role of Lhs1 during αENaC and ΔG αENaC retrotranslocation, which is 
downstream of ubiquitination in the process of protein degradation from the ER.  By exposing our 
SDS-PAGE separated samples to phosphorfilm, we can determine the percentage of ubiquitinated 
material that is retrotranslocated.    After quantifying the amount of ubiquitinated protein in the 
supernatant, I found that the level of ubiquitinated αENaC and ΔG αENaC that is extracted out of 
the ER-enriched microsomes is roughly half as much in the lhs1Δ reactions compared to the 
wildtype (BY4742) reactions (part D).  This result suggests that Lhs1 plays an important role in 
the efficient retrotranslocation of αENaC prior to degradation.           
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Figure 22. Lhs1 recognizes a relatively insoluble population of αENaC and is required for 
the efficient retrotranslocation of αENaC. 
(A) ER-enriched microsomes purified from the lhs1Δ yeast strain expressing the HA-tagged 
αENaC were treated with the non-ionic detergent, n-Dodecyl-β-D-maltoside (DDM).  As 
controls, microsomes were incubated in buffer or in the presence of the strong ionic detergent, 
sodium dodecyl sulfate (SDS).  Samples were centrifuged at 18,000 x g and 4°C for 10 min.  
Fractions were split and proteins were separated on polyacrylamide gels.  αENaC was visualized 
using antisera against HA (ENaC) and Sec61, an ER-resident protein which served as a control 
for microsome solubilization.  The data are representative of N = 4 +/-SEM, *p<0.01.  (B)  
lhs1Δ-derived ER-enriched microsomes containing HA-tagged ΔG αENaC were treated similarly 
as in (A).  The data are representative of N = 4 +/-SEM.  (C) In vitro 125I-ubiquitination assays 
were performed as described in Materials and Methods with ER-enriched microsomes containing 
ΔG αENaC purified from either wildtype (BY4742) or mutant (lhs1Δ) strains.  Ubiquitinated ΔG 
αENaC was immunoprecipitated with anti-HA antisera and resolved on polyacrylamide gels.  
Data represent N = 6-9 experiments +/-SEM, *p<0.05.  (D) In vitro 125I-ubiquitination and 
retrotranslocation assays were completed as described in Materials and Methods using ER-
enriched microsomes from wildtype (BY4742) and lhs1Δ strains containing either αENaC or ΔG 
αENaC.  Data represent N = 2 +/- the range in the data. 
B.4 DISCUSSION 
During the ERAD of a misfolded substrate, a complex assembly of cellular machinery is 
responsible for recognition, ubiquitination, retrotranslocation, and the subsequent degradation of 
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the substrate.  Many of these components have been investigated and their roles have been 
identified (for review, see Chapter 1).  However, the list of factors that play a role in ERAD 
continues to expand.  This expanding list could potentially be due to the large number of diverse 
substrates that undergo ERAD.  For example, Lhs1, an ER luminal nucleotide exchange factor 
(NEF) for the ER luminal Hsp70, Kar2, is one such factor recently discovered to play a role in the 
degradation of the alpha subunit of the heterotrimeric protein, ENaC (345).  Prior to this study, 
little was known about why αENaC is recognized by Lhs1 and what role Lhs1 plays in the 
degradation of αENaC.  In order to address these questions, I worked with several members of the 
Brodsky lab. 
The first question, why does Lhs1 recognize αENaC as a misfolded substrate, is an 
important question because much less is known about what characteristics lead to the selection of 
a protein for ERAD.  Other labs have suggested that recognition of an ERAD substrate is due to 
the exposure of internal secondary protein structure (270-272), hydrophobicity (92, 273), or loss 
of post-translational modifications (274, 275).  In order to test which characteristics of αENaC 
lead to the selection by Lhs1 for ERAD, I utilized a detergent solubility assay I developed in the 
lab.  Interestingly, the non-glycosylated population of αENaC is roughly 50% less soluble than the 
glycosylated population (part A).  Unexpectedly, the solubility of the non-glycosylated population 
of αENaC was not affected by Lhs1 (part B).  This result was surprising as some ER luminal 
chaperones, such as Kar2, help maintain the solubility of ERAD substrates prior to degradation 
(346, 347).  Similar functions in maintaining substrate solubility have been observed for the Kar2 
mammalian homologue, BiP, as well, during ERAD (348).   
Since Lhs1 does not appear to be important for maintaining the solubility of non-glycosylated 
αENaC, I investigated a potential role for Lhs1 in αENaC ubiquitination and retrotranslocation.  
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It is known that other Hsp70s and their cochaperones, such as the cytosolic Ssa1 and Ydj1, are 
required for integral membrane ERAD substrate ubiquitination (19, 141).  However, in in vitro 
ubiquitination assays, the absence of Lhs1 led to a 3-4 fold increase in ΔG αENaC ubiquitination 
(part C).  Instead, it appears that Lhs1 plays an important role in the efficient retrotranslocation 
of αENaC.  In the absence of Lhs1, both ubiquitinated αENaC and ΔG αENaC were less 
efficiently retrotranslocated than in reactions using membranes from wildtype cells (part D).  The 
mammalian homologue for Lhs1, GRP170, was also identified to be important for the 
retrotranslocation of ERAD substrate (349).  However, one important difference between Lhs1 
and GRP170 during ERAD is the lack of dependence on its nucleotide exchange factor activity 
for the degradation of αENaC (345, 349).  Therefore, it will be important to identify the exact 
role of Lhs1 in the retrotranslocation of αENaC in the future. 
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